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Abstract
Rheumatoid arthritis (RA) is an autoimmune condition that causes chronic joint pain and
destruction. The current standard regimen of monotherapy disease modifying antirheumatic drug (DMARD) treatments may not be as effective as that of combination
therapy of a DMARD and a biologic agent in treating RA. The purpose of this study was
to answer the question, is there a difference in the therapeutic efficacy of combination
DMARD treatments with a biologic, compared to monotherapy DMARDs without a
biologic, in U.S. Caucasian women between the ages of 30 and 60 that have been
diagnosed with RA? Guided by the theoretical framework of integrated theory from
evidence-based practices, this study used a cross sectional study design and data from
AR-PoWER Patient Powered Research Network. Having adjusted for age, logistic
regression was used to examine the association between the therapeutic effectiveness and
treatment modality (DMARDs without a biological agent versus DMARDs with a
biologic agent; OR = 1.15, 95% CI = 0.57-2.33). The result indicated that there was no
significant association between treatment effectiveness and treatment modality. A
positive social change implication of this finding is that the assessment of the efficacy of
DMARDs with or without a biologic agent may warrant further investigation in which
studies with large sample sizes that include various populations are used. In this study,
there was no difference between the monotherapy and combination therapy treatments for
Caucasian women aged 30 to 60 years. However, a future study with a larger sample size
that compares diverse populations may produce a different outcome.
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Chapter 1: Introduction to the Study
Background
Rheumatoid arthritis (RA) is a chronic autoimmune disorder that causes abnormal
inflammation of the joints (Zengin et al., 2018). It can attack organs such as the heart and
the lungs, tissues such as muscle and cartilage, and ligaments and bone (Shiel, 2018). RA
causes chronic swelling that results in permanent joint destruction and severe pain (Shiel,
2018). The aggressiveness of this disease can cause permanent disability (Shiel, 2018).
An estimated 23.5 million United States citizens have been affected by the autoimmune
effects of RA (Alam et al., 2017). The disease is estimated to be 2-3 times more common
in women than men (Bokarewa, 2014). RA can affect all ages and races (Shiel, 2018).
RA is known to shorten the lifespan of patients and increase their risk of mortality (Kelly
& Hamilton, 2007). One of the common treatment options for RA is the use of diseasemodifying, anti-rheumatic drugs (DMARDs), but these treatments are still observed to be
less effective than combination treatments with a biologic in reducing the risk of
mortality due to their suppression of the immune system by targeting the entire system
(Iliades, 2017). Researcher Chris Iliades (2017) observed Janus Kinases (JAK) pathways
for a broad population that included all races and genders. His study showed that
DMARDs were less effective than combination treatments. Because combination
treatments have not been observed at specific population levels, this study observed
Caucasian women from ages 30 to 60 years. Combination treatments can include other
DMARDs or the use of biologics. Biologics, such as tumor necrosis factor (TNF)
blockers, are different from DMARDs because these drugs target specific areas of the
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inflammatory process (Iliades, 2017), whereas DMARDS inhibit the production of
cellular immune response to antigens. There are biologics that target other immune
pathways, such as interleukin pathways and JAK pathways, which was the pathway that
Iliad studied.
Problem Statement
The therapeutic efficacy of combining DMARDs and biologics has never been
comprehensively studied at population data levels of Caucasian Alabamian women aged
30 to 60 years who have been diagnosed with RA. Biologics may work well in
combination with DMARDs, such as Plaquenil or methotrexate, that interfere with cell
communication in autoimmune diseases by hindering the antigen processing (Goldman et
al., 2000). These immunosuppressants can help prevent infection by reducing the
frequency of producing antibodies to the biologic agent (Cunha, 2016). Adequate
research has not been performed to provide data on the effectiveness of combination
treatments with a DMARD and a biologic. Therefore, further research is needed on the
comparative analysis of combination treatments with and without biologic agents
(Gradual et al., 2014). The importance of this study was that it compared the results
obtained in the target population when using a DMARD with and without a biologic.
Methotrexate is the standard first choice treatment of physicians and insurance providers.
Insurance companies may require patients to have a trial and failure on this drug before
they can move to another DMARD treatment, such as Plaquenil, or a biologic. The
observation and comparison of drug treatments was performed on a specific target
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population of U.S. citizen women aged 30 to 60 years collected from a national database
through statistical data analysis. The DMARDs work by stopping inflammatory cells
from being produced, and the biologics work to stop the immune system from being
overactive, and together the two may shorten the disease progression and allow the
patient to feel pain relief in a timely manner (Levine, 2017).
Purpose of the Study
The purpose of the study was to compare the therapeutic efficacy of RA
treatments, a DMARD, such as Plaquenil or methotrexate, which are the most commonly
used DMARDs, with and without a biologic, in a specific population. This study used a
cross sectional study design and data from Arthritis Partnership with Comparative
Effectiveness Researchers (AR-PoWER), a Patient Powered Research Network. Having
adjusted for age, logistic regression was used to examine the association between the
therapeutic effectiveness and treatment modality (DMARD with and without a biologic.)
The typical challenges of research on population data are time, expense, and clinical
conditions. The plan to control for these challenges is the establishment of a target
population and written approvals to access national databases. The target population for
this research was specifically gender-based and population-based. It included Caucasian
women that are United States Citizens, aged 30 to 60 years, because RA is most common
in women between those ages (Arthritis Foundation, 2017). It is of high importance to
control RA in these patients by suppressing the inflammation in a timely manner and
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sustaining overall improvement and wellbeing of the patients (National Rheumatoid
Arthritis Society [NRAS], 2019).
Significance of the Study
This study enhanced the knowledge on how DMARD treatments could be used in
conjunction with a biologic to control for the inflammatory responses to prevent pain,
severe bone erosion, joint deformity, and organ damage (Guo et al., 2018). Combination
treatments can be effective for some RA patients but are not necessarily effective for all
RA patients, because the prescribed treatments for the autoimmune disease will respond
to each individual’s cellular structure differently. There was a knowledge gap between
the use of DMARD monotherapy versus combination biologic-DMARD therapy for the
therapeutic efficacy of RA treatments, but this study provided knowledge that helped
close the gap for Caucasian women aged 30 to 60 years that have been diagnosed with
RA. The statistical findings were that a DMARD and biologic work together to provide
relief to the patient with RA, but not necessarily better than DMARDs alone. In some
patients, an early diagnosis together with a combination therapy could provide relief by
suppressing the inflammation and blocking the inflammatory pathway in a shorter time
frame than monotherapy treatments because biologics cause cells to respond quicker than
DMARDs (Rein & Mueller, 2017). A combination drug treatment, such as a Plaquenil
DMARD and a Remicade biologic, may seem to be an effective therapy, considering
DMARDs work by stopping inflammatory cells from being produced, and the biologics
work to stop the immune system from being overactive (Levine, 2017). However, the
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findings of this study did not support the therapeutic efficacy of the two treatments taken
in conjunction. This research was performed to fill the gap in the literature as to whether
combination therapy consisting of a DMARD and a biologic should be the initial
standard drug treatment for U.S. Caucasian women between the ages of 30 to 60 years
that have been diagnosed with RA. Public health practitioners, insurance providers and
physicians are the ones that design the policies of standard regimen for the disease. This
research can possibly make an impact on their policies of treatments for patients being
diagnosed with RA.
This study did not find that combination therapy is better than the current standard
monotherapy, but it may continue to cause social change through statistical evidence that
a combination treatment could be used to decrease the severity of joint pain for some
patients, but is not statistically therapeutic for all patients to control the pain ailments and
disability that occur with RA. This study may help bring social change by providing
evidence related to the efficacy of combination therapy for RA, compared to the standard
monotherapy treatment, which would be valuable in developing more effective clinical
and/or public health practices for healthcare policy regulations to ensure regulatory
standards are being met. A social change implication of this study’s findings is that the
assessment of the efficacy of DMARDs with a biologic agent and DMARDs without a
biologic agent may warrant further investigation in studies with large sample sizes that
include various populations.
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Rationale of Theoretical Framework
The use of integrated theory from evidence-based practices uses data from
patients that details their effectiveness of the drug treatments that would allow for more
accurate decision making to be made in comparing monotherapy and combination
therapy for RA patients. Integrated theories are based on evidence in research
(Gopalakrishnan & Ganeshkumar, 2013). Integrated theories make connections through
knowledge and practice. Integrated theory from evidence-based practice is customarily
used to examine intervention efficacy and safety (Pipe, 2017) and is adopted as an
appropriate framework for guiding the comparison of therapeutic efficacy of RA
treatments. There are particular areas of interest for the use of integrated research, such as
epidemiology, health promotions, health risk factors, clinical pathology, preclinical
biology and disease mechanisms, and models in medicine and biosciences (National
Research Council, 2018). Stakeholders that would be interested in using the integrated
research model would be clinicians, scientists, health providers, pharmaceuticals, and
bio-tech industries (National Research Council, 2018). The research model targets
tailored care, better quality of life, and healthcare maintenance and promotion (National
Research Council, 2018). The end users of the research model are the patients that benefit
from the therapeutics (National Research Council, 2018). This proposed research
framework has the potential to inspire questions and challenge method assumptions (Din
& Paskevich, 2013).
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Quantitative Research Question
Is there a difference in the therapeutic efficacy of combination DMARD
treatments with a biologic, compared to monotherapy DMARDs without a biologic, in
U.S. Caucasian women between the ages of 30 and 60 that have been diagnosed with
RA?
This study was conducted as quantitative research. It consisted of secondary data
for comparative analysis. The possible differences in the variables were the focus of the
exploration. The goal was to reveal a variation of differences in the forms of treatments
as the basic formation of statistical analysis. It was beneficial to determine the statistical
impact of the variables: DMARD therapy without a biologic, in comparison to the
DMARD with a biologic.
Null Hypothesis: There is no difference in the therapeutic efficacy between
combination therapy and monotherapy in treating U.S. Caucasian women between the
ages 30 and 60 that have been diagnosed with RA.
Alternative Hypothesis: There is a difference in the therapeutic efficacy between
combination therapy and monotherapy in treating U.S. Caucasian women between the
ages 30 and 60 that have been diagnosed with RA.
Definition of Terms
Antigen: A molecule in the body that triggers an adaptive immune response.
(Arduengo, 2020). In reference to autoimmunity, the antigen is a self-antigen that triggers
an immune response on itself.
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Articular: The synovial joints (Bhosale & Richardson, 2008).
Autoimmune: A self-damaging condition in which the cells mistakenly attack the
body in response to a malfunction of the immune system (Zengin et al., 2018).
Biologic Agents: Drugs that are complex medicinal products from living
organisms. This class of drugs is used to treat a variety of diseases, including
autoimmune diseases, cancer, growth disorders, and rare genetic conditions (Cunha,
2016).
Clinical Conditions: The identification of a patient’s diagnosis that is associated
with one specific health condition or more than one health condition (Tilea et al., 2018).
Disease-modifying antirheumatic drugs: A class of drugs made of monoclonal
antibodies that are used to treat RA, as well as other autoimmune diseases, to suppress
joint damage, induce or maintain remission, reduce flare-ups, and sustain disease control
(Guo et al., 2018).
Immunogenicity: The ability of an antigen to trigger a cell-mediated immune
response (Sauna, 2020).
Immunosuppressants: A class of drugs used for autoimmune diseases to weaken
the immune system to suppress the damaging reaction that is being induced on the body
by its own cellular activity (Cunha, 2016).
Methotrexate: A folic acid analogue drug that is used as a chemotherapeutic agent
in the treatment of RA and other autoimmune diseases as well as cancer (Teja &
Damodharan, 2018).
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Plaquenil: An anti-inflammatory, hydroxychloroquine (HCQ) drug that is used as
a suppressive treatment for RA and lupus, and it is also used against malaria (American
College of Rheumatology, 2018). It interrupts cellular communication of the immune
system to prevent joint damage and reduce the risk of long-term disability (American
College of Rheumatology, 2018).
Population Data: Information gathered from a specific group or population
identified by characteristics for data. In this research it is women with RA (Taylor et al.,
2019).
Rheumatoid Arthritis: A chronic autoimmune disorder that causes abnormal
inflammation of the joints (Zengin et al., 2018).
Suppress: The reduction or inhibition of a
reaction of the immune system (Cunha, 2016).
Synovial: A secreted membrane fluid that lubricates the joints (Bhosale &
Richardson, 2008).
Therapeutic Efficacy: The maximum response of a drug to achieve beneficial
therapy/treatment (Mandal, 2018).
Tumor Necrosis Factor: A protein that is capable of inducing apoptosis, cell
death, of a tumor cell through pro-inflammatory actions (Shiel, 2019). Cytokines are the
small proteins that are released to signal the process that causes inflammation (Shiel,
2019).
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Tumor Necrosis Factor-IR (TNF-IR): Patients who exhibit inadequate response to
TNF (Shiel, 2019).

11
Chapter 2: Literature Review
Introduction
RA is a common chronic autoimmune disease with disabling joint inflammation.
The inflammatory disease causes chronic pain, stiffness, and swelling of the joints. It
affects approximately 1% of the United States population and has an annual mortality
rate of 26 per 1000 persons (95% CI, 25.87-27.97; Dellabella, 2018). The disease is twice
as prevalent in women compared to men (Cherascu, 2011). The general range of affected
ages are 40 to 70 years (Cherascu, 2011). However, all ages can be affected by RA.
Patients suffering from RA endure chronic pain that can be localized to select
body parts such as the knees or can be all over the body. The inflammation caused by the
disease affects the tissues that surround the joints as well as other organs in the body
(Kerkar, 2018). A person’s immune system attacks the healthy tissues of the body as if it
were using antibodies to destroy invaders like pathogens that cause infections (Kerkar,
2018). Therefore, patients diagnosed with this autoimmunity have antibodies in their
blood that target the tissues of the body resulting in inflammation of the joints (Kerkar,
2018). The chronic inflammation of the disease may result in damage to the bones,
ligaments, and cartilage that leaves the joints deformed (Kerkar, 2018). The symmetrical
arthritis of the smaller joints refers to the arthritis that attacks hands and feet (Cherascu,
2011). However, bilateral arthritis attacks bilateral hand joints, which consist of
interphalangeal joints (phalanges), metacarpophalangeal joints (knuckles),
carpometacarpal joints, and wrist joints and/or bilateral foot joints, which consist of

12
interphalangeal joints (phalanges), metatarsophalangeal joints (base of phalanges),
tarsometatarsal joints (mid-foot), talonavicular joint (talus side of foot), and tibio-talar
joint (ankle) (Arthritis Foundation, 2017). The larger joints that may be affected by the
inflammatory processes are the shoulders, knees, hips, and axial skeleton (Cherascu,
2011). The functional impairments of the disease result in the loss of productivity and an
increase in disability (Cherascu, 2011). The disease can be so severe that it causes
unrelenting joint destruction that can lead to amputation if not treated before the joint
becomes deformed (Cherascu, 2011).
Figure 1
Rheumatoid Arthritis Deformity Example

(Mayo Clinic, 2018)
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Risk Factors of RA
RA causes chronic inflammation of the synovial membrane which lines the joints
and connects the bone and cartilage (Jimenez-Boj et al., 2005). Thus, the joints are not
the only part being injured as neighboring structures are also damaged (Jimenez-Boj et
al., 2005). In fact, RA is capable of attacking all parts of the body, including the organs,
bones, blood, and bone marrow. Specific organs and areas that may be affected by RA
are the skin, lungs, heart, blood, eyes, mouth/gums, kidneys, liver, spleen, nervous
system, bones, and bone marrow (Dunkin, 2015).
Parts of the Body Affected by RA:
1. Skin: Half of the patients with RA may develop rheumatoid nodules under the
skin in bony areas that are exposed to pressure, the feet being a good example
(Dunkin, 2015). These nodules are sensitive and can diminish or recede with
DMARD treatment (Dunkin, 2015). Rashes and skin ulcers are capable of
forming due to the underlying inflammation of the skin itself or the blood
vessels (Dunkin, 2015).
2. Lung: About 80% of the patients with RA experience lung inflammation that
may cause interstitial lung disease and consequently shortness of breath
(Dunkin, 2015). If persistent inflammation occurs, pulmonary fibrosis can
develop, which is scarring of the lungs (Dunkin, 2015). The result is the
thickening of the pulmonary wall and decreased oxygen. Rheumatoid nodules
are also capable of forming inside the lungs (Dunkin, 2015).
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3. Heart: About 50% of the patients with RA experience inflammation of the
heart lining known as pericarditis that results in chest pain (Dunkin, 2015).
However, treatment with DMARD therapy and biologics can control the
inflammation of the pericardium (Dunkin, 2015). Plaque from damaged blood
vessels (atherosclerosis) can cause heart attack and strokes in patients with
RA (Dunkin, 2015). DMARDs and biologics can reduce cardiovascular risks
(Dunkin, 2015).
4. Blood: Persistent inflammation can lead to a reduction of red blood cells thus
causing anemia, which results in low-iron or low serum ferritin (Dunkin,
2015). Inflammation of the blood and blood vessels can potentially cause
blood clots by increasing the platelet counts (Dunkin, 2015).
5. Eyes: RA patients are at risk of developing scleritis, which is an inflammation
of the sclera of the eyes resulting in pain, redness, blurred vision, and light
sensitivity (Dunkin, 2015). Another type of inflammation of the eyes is
uveitis. The inflammation targets the area between the sclera and the retina
and is capable of causing blindness without treatment (Dunkin, 2015).
Inflammation can cause Sjogren’s syndrome, which damages the tearproducing glands, resulting in severe dry and gritty eyes (Dunkin, 2015).
6. Mouth/Gums: Inflammation of the moisture-producing glands in the mouth
can lead to dry mouth and gum disease; bacteria can develop and cause tooth
decay (Dunkin, 2015).
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7. Kidneys: If a patient does not pursue a therapeutic regimen of DMARDs
and/or biologics and chooses to treat RA with only non-steroidal antiinflammatory drugs (NSAIDS) to alleviate pain and swelling, damage to the
kidneys may occur (Dunkin, 2015).
8. Liver: Overuse of Tylenol and methotrexate therapy can result in liver
damage (Dunkin, 2015).
9. Spleen: Longstanding untreated RA can lead to Felty syndrome, which results
in an enlarged spleen and low white blood cell counts (Dunkin, 2015). The
condition increases the patient’s risks of bacterial infections, cancers, and
lymphoma (Dunkin, 2015).
10. Nervous System: Inflammation flares of tissues can lead to compression of
nerves resulting in numbness and tingling (Dunkin, 2015). Carpal tunnel
syndrome is a common concern with RA due to compressing of nerves by
inflamed tissues of the wrist (Dunkin, 2015). The nervous system normally
detects inflammation in the tissues, but RA can cause an imbalance in the
nervous system (Koopman et al., 2016). RA reduces the activity of the
parasympathetic nervous system and causes the sympathetic nervous system
to become overactive (Koopman et al., 2016).
11. Bones: RA causes chronic inflammation of the bones resulting in the loss of
bone density and vitamin D (Dunkin, 2015). The bones and the joints become
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thin and brittle (Dunkin, 2015). DMARD therapy and biologic treatments can
improve the bone condition.
12. Bone Marrow: RA can infiltrate the bone marrow and disrupt the production
of red blood cells (Bouchnita et al., 2016). This is consistent with the cause of
anemia and lack of oxygen-binding proteins in the red blood cells.
13. Cancer: RA is known to be associated with a number of cancers, including
lymphoma, lung cancer, and non-melanoma skin cancer, and possibly
cervical, prostate, and melanoma skin cancers, but a decreased risk of
colorectal and breast cancers (Lange et al., 2016).
Patients with RA have a shorter life expectancy than the general population
mostly due to the significant increase in comorbidities such as heart attacks and strokes
(Emrich, 2009). RA is commonly referred to as a systemic illness or rheumatoid disease
since chronic inflammation affects multiple organs of the body (Kerkar, 2018). Vasculitis
is one of the serious complications that results from RA (Cleveland Clinic, 2019). The
comorbidity occurs when the blood vessels become inflamed. The arteries and veins may
become weakened causing little or no blood flow to the skin, nerves, and internal organs
(Cleveland Clinic, 2019). Vasculitis of the larger arteries that decreases or stops the blood
flow to tissue sites can ultimately result in a stroke or heart attack (Cleveland Clinic,
2019). Rheumatoid vasculitis occurs in the more severe RA cases. Patients who have
suffered from RA for many years are likely to experience the illness (Cleveland Clinic,
2019). The condition occurs in less than 5% of RA patients (Cleveland Clinic, 2019).
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Inflammation and swelling of the heart’s outer wall or heart muscle itself is
another serious complication among RA comorbidities. The swelling causes patients to
experience chest pain and decreased cardiac output, which can lead to congestive heart
failure (Emrich, 2009). The inflammation and swelling of the heart’s outer wall are called
pericarditis (Emrich, 2009). Inflammation of the heart muscle is called myocarditis
(Emrich, 2009). The two conditions weaken the functionality of the heart leading to
congestive heart failure, which is a decrease in the pumping of the blood in and out of the
heart. Although RA has high morbidity and mortality rates, it is often not the immediate
cause of death but rather predisposes the patients to comorbidities that may directly cause
death (Molina et al., 2015).
Diagnosis of Rheumatoid Arthritis
Through rheumatoid factor (RF) and anti-citrullinated protein antibody (tested as
anti-cyclic citrullinated peptide [anti-CCP]), physicians, specifically rheumatologists, are
able to establish the presence of the autoimmune disease (Cubero et al., 2016). Anti-CCP
and RF are immunoglobulin M (IgM) antibodies produced by the immune system in
response to foreign cells that produce inflammatory symptoms (Freeman, 2018). RF
intensifies the inflammatory response of macrophages induced by the specific immune
complexes of RA (Laurent et al., 2015). Citrullinated proteins are found in the synovial
tissue, and they diminish amino acids such as arginine that change the charge of the
protein which could potentially be a cause for the autoimmune disease because of its
inability to interact with neighboring proteins (Van Venrooij and Pruijn, 2000). Proteins
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must interact with other proteins to function and communicate. Anti-CCPs are present in
60- 70% of RA patients, and RF is present in 70- 90% of RA patients (Freeman, 2018).
These markers can be found in early or late-stage disease (Freeman, 2018). The more
aggressive the units of the lab results are for these tests, meaning the results exceed the
normal range, can determine the aggression of the disease as well as a more aggressive
treatment option (Freeman, 2018). These are specific biologic markers in the DNA that
are associated with the pathogenesis of RA (Liao et al., 2009). The U.S. National
Institutes of Health defined biomarkers as characteristic diagnostic indicators to measure
the activity of the disease (Taylor, 2019). To fully diagnose a patient with RA, a positive
anti-CCP blood test in conjunction with a positive RF along with physical examinations,
imaging, and other blood tests that measure inflammation levels are required (Freeman,
2018). However, x-rays may not show any signs of disease activity in early RA. On the
other hand, inflammation and swelling are typically present on physical examination.
Anti-CCP is used in conjunction with RF because RF alone can be present in other
illnesses, such as hepatitis (Freeman, 2018). Therefore, the two biomarkers must be
positive for a more accurate seropositive diagnosis of RA (Freeman, 2018).
Autoimmune conditions like RA are mostly identified by autoantibodies.
Autoantibodies are just like normal antibodies that are immune proteins created by the
immune system, except autoantibodies mistakenly target the wrong cells or proteins as
the antigen. RA patients might have a positive antinuclear antibody test result. The test is
of prognostic importance among juvenile RA cases (Ravelli et al., 2005). C-reactive
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protein (CRP) and fibrinogen are immunological proteins produced by the liver (Babikir
et al., 2017). They are used as biomarkers to monitor the status of inflammation in the
body (Babikir et al., 2017). Erythrocyte sedimentation rate (ESR) is another blood test
performed to check the inflammation in the body (Babikir et al., 2017). CRP and ESR
levels mostly rise in RA, but they can also increase in other inflammatory diseases. The
acute phase reactants formulate part of the RA classification process by serving as
inflammatory markers (Aletaha et al., 2010). CRP and ESR levels help to measure RA
disease activity and elicit medication response as well.
Autoimmunity can cause disruptions and complications throughout the entire
immune system. A decrease in the inflammatory articular disease reduces the
autoantibodies being released that are attacking healthy cells. Besides, some ways have
been used in differentiating RA from other arthritic disorders. Structural changes are seen
using conventional radiography or the imaging methods used to distinguish RA from
other arthritic disorders in their early stages. RA is less destructive in the early stages, but
it accumulates over time by damaging bone, cartilage, and tissue. The longer RA is left
untreated, the more damage it causes, which increases pain, deformity, and potential
infections, and decreases lifespan.
In the last 10 years, the process of fighting arthritic disorders has been done using
DMARDs (Chatzidionysiou et al., 2017). The most commonly used DMARDs include
methotrexate and Plaquenil. However, the development of new biological agents has
made it possible to manage the signs and symptoms associated with RA. Early treatment
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of RA improves the likelihood of suppressing the disorder. In fact, early treatment of RA
has saved patients from the severe effects of the disease. Current RA clinical treatment
trials have been hindered by inadequate numbers of patients in the early stage of disease.
Consequently, researchers have failed to establish the effectiveness of an early
intervention therapy to prevent the progression of the disorder to later stages.
Classification criterion is the standardized way of defining the presence of RA
disorder in an individual. Taking the appropriate steps of diagnosing the disease by
observing the specific markers doctors use to diagnose RA is classification criterion.
However, careful clarification is involved because some markers can represent another
autoimmune disease. For example, CRP and ESR are inflammatory markers for RA but
can also be seen in Lupus. However, adequate elevation levels of RF and anti-CCP with
ESR can represent autoimmunity for RA. Through the use of the classification method,
healthcare personnel can group individuals by whether or not they have RA. Further, the
grouping has helped in clinical trials on individuals who might be genetically receptive or
who are already suffering from the disorder symptoms and being diagnosed. Again, the
classification criteria have helped investigators to conduct various studies that relate to
RA (Ajeganova et al., 2017). Through the research, scientists have managed to develop
stringent measures of managing the disease. Doctors have applied the criteria in many
parts of the world to address the effect and treatment of the disease. The American
College of Rheumatology (ACR) came up with the classification criteria used commonly
by doctors in many parts of the world (Ajeganova et al., 2017). However, the criteria
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developed by the ACR are used in diagnosis to provide the benchmark for defining the
presence of the condition. The classification criteria established by ACR distinguishes the
afflictions of RA from other known rheumatology disorders, such as psoriatic arthritis.
Etiology and Classification of RA
Modern therapies aim to make sure RA patients do not go through the chronic
stages of the disease as indicated in the 1987 criteria for RA disorder. However, experts
from both ACR and the European League against Rheumatism (EULAR) came together
to develop a more simplified way of approaching the diagnosis and treatment of RA
disorder (Shiboski et al., 2017). The main aim of the ACR and EULAR experts was to
devise classification criteria that would address methods of handling early cases of RA.
The approach led to the development of the 2010 ACR/ EULAR classification criteria for
RA.
RA’s etiology remains multifactorial just like other autoimmune conditions;
meaning it has various causes and influences. Familial clustering alongside monozygotic
twin studies revealed genetic susceptibility with about half of RA risk being traceable to
genetic factors (Chung et al., 2007). Genetic RA associations include human leukocyte
antigen-DR45 and DRB1 among other alleles referred to as shared epitope (Chung et al.,
2007). Genome-wide studies pointed to other genetic signatures that raise the chances of
acquiring RA and other autoimmune conditions, like cluster-of-differentiation-40 (CD40)
and STAT4 gene (Chung et al., 2007). A cluster-of-differentiation (CD) surface protein
acts as a marker protein on an antigen-presenting cell, such as macrophages, dendritic
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cells, and B-cells. There is oxidative damage implicated in the pathogenesis of RA which
causes an imbalance between the reactive oxygen and the biological system’s reaction to
antioxidants (Karlson et al., 2008). Free radicals have been found within the rheumatoid
synovium and in the plasma (Karlson et al., 2008). RA can be caused by environmental
factors, such as long-term smoking and various infectious diseases, or it can be caused by
genetic predisposition (Edwards & Cooper, 2006). Potential infectious candidates that
could trigger this autoimmune response are retroviruses, Epstein-Barr Virus, Fifth
Disease, Escherichia coli, Mycobacterium tuberculosis, and Proteus mirabilis (Edwards
& Cooper, 2006). These infections can increase the antibody titers found in RA patients
(Edwards & Cooper, 2006). Genetic factors are responsible for at least 50% of the risk,
while environmental factors potentially make-up the rest (Edwards & Cooper, 2006).
Individuals from families with genetic history of the disease, the elderly, and
women are at a higher risk of the disease than those that are not of these categories.
Gender and age differentials directly contribute to the disease prominence (Firestein &
Kelley, 2009). Current and previous cigarette smokers have higher chances of contracting
RA (Costenbader et al., 2006). Pregnancy is known to cause RA remission due to
immunologic tolerance (Kaaja & Greer, 2005). Parity exhibits a long-lasting impact, and
it is notable that RA is less likely to occur among pregnant women compared to
nulliparous women (Guthrie et al., 2010). However, during pregnancy there is a spike of
estrogen and progesterone. Hormones can play a huge role in woman in various ways.
Estrogen imbalances have been thought to make an impact as a potential risk factor of the
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disease. Recently, researchers Grant Hughes and Divaker Choubey studied the hormonal
effect on RA (Lunardo, 2016). They found that at high levels, these two hormones
suppress RA, such as during pregnancy, but at lower levels, such as during menopause,
hormone replacement and oral contraceptives are associated with a greater risk of RA
(Lunardo, 2016). More research is required on the hormonal effect of RA, but researchers
have confirmed that estrogen and progesterone are “dominant risk modulators” for a
similar autoimmune disease called Lupus (Lunardo, 2016). A risk of disease production
through breastfeeding was a concern until a recent study was performed and found that
long-term breastfeeding of greater than 13 months was associated with a significant
reduction of RA (Liao et al., 2009). Therefore, breastfeeding reduces the chances of
advancing to RA among women who breastfeed. High birthweight is a potential risk
factor for RA. A recent study focused on this risk and found that babies weighing greater
than 9.9lbs at birth had at least a two-fold risk of developing RA compared with babies
who were 7.0 - 8.5lbs at birth (Liao et al., 2009). The disease is high during menstrual
cycles and intermittent menstrual periods; increasing the woman’s risk of advancing to
RA (Karlson et al., 2004). The hormone changes that occur during menstrual cycles
disrupt the inflammatory markers in the body causing flare-ups of RA.
RA creates inflammatory pathways that result in synovial cell proliferation within
the joints. Over secretion of proinflammatory cytokines like TNF, JAK and interleukin-6
(IL-6) makes the destruction process take place quickly (Scott et al., 2010). TNF is a
protein that is capable of inducing apoptosis, cell death, of a tumor cell through pro-
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inflammatory actions (Shiel, 2019). Elevated levels of IL‐6 have been reported in the
serum and synovial fluid of RA patients and found to correlate with inflammation and
disease activity (Genovese, Fleischmann & Kivitz, 2015). A humanized inhibitor of IL‐6
activity has been shown to be elevated in RA, but an administered combination of
therapeutics with a DMARD and a biologic may reduce the pro-inflammatory cytokine
(Genovese et al., 2015). Cytokines are expressed at high levels in the joint tissues
resulting in inflammation and articular destruction (Taylor & Feldman, 2009). “TNF was
the first cytokine to be fully validated as a therapeutic target for RA” (Taylor & Feldman,
2009). Although TNF is the preferred target for biologic therapy, interleukins have also
been validated for target therapy (Taylor & Feldman, 2009).
Patients diagnosed with RA mostly exhibit pain and stiffness across various joints
of the body. The most affected joints are proximal interphalangeal joints, wrists, and
metatarsophalangeal joints. Morning stiffness that lasts beyond an hour could be a form
of inflammatory etiology. Dreadful swelling from synovitis becomes visible at any stage.
The subtle synovial thickening might be palpable when examined. Before the onset of
clinically diagnosable swelling, the patient might develop indolent arthralgias. Systemic
symptoms like fatigue, low-grade fever, and weight loss might occur once the disease
fully develops or matures.
ACR and EULAR worked together in 2010 to establish newly distinct
classification measures for RA (Aletaha et al., 2010). The newer techniques express
efforts towards early RA diagnosis among patients that never met the 1987 ACR
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classification criteria through observation of specific protein markers and magnetic
resonance imaging (MRI) of bone erosion. Moreover, a group of Dutch researchers
developed clinical prediction rules for RA (Van der Helm-van Mil et al., 2007; Mochan
& Ebell, 2008) whose purpose was to identify patients with undifferentiated arthritis that
could potentially develop RA. As a result, this standard involves follow-up and referral
processes. After doctors diagnosed a patient with RA there were standards for follow-up
appointments to re-evaluate the progress of the disease and the effectiveness of the
medications. If a doctor was not able to make an accurate diagnosis, then a referral was
performed. It is best to see an actual rheumatologist for evaluation of RA opposed to
general physicians because the rheumatologists are more knowledgeable of the
biomarkers to evaluate.
Immunology Alongside RA
The understanding of the pathophysiological aspects of RA is difficult. There is
evidence that RA plays a pivotal role on the immune response, but researchers
understanding of the disease is far from complete (Kavanaugh & Lipsky, 2012). The
immune system responds when it is activated by antigens that may include proteins being
seen as antigens. For people with RA, their immune system is activated consistently due
to an immune response of releasing cytokines, interleukins, and TNF in response to
healthy cells that are foreseen as antigens. As a result of the autoimmunity activating an
immune response, the body becomes weak and exhausted. There have been vigorous
experimentations for defining the immunopathological basis of disease to create
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therapeutic agents and improved therapies (Kavanaugh & Lipsky, 2012). The molecular
design to treat the damaging immunological responses caused by RA is to target specific
parts of the immune system that are responsible for the reaction without causing further
damage to the filtering organs (Kavanaugh & Lipsky, 2012). The primary complete blood
count alongside the differential and assessment of the hepatic and renal functions
fundamentally assists in determining the treatment options. For instance, patients that
suffer from insufficient renal function or significant thrombocytopenia would not be
prescribed a NSAID due to an increase in renal toxicity. Of those RA patients that
experienced problems or difficulty with their hemoglobin levels or hepatic functions, 3360% incurred chronic mild anemia (Wilson et al., 2004). This is due to a drop in red
blood cells and the reduction of oxygen needed to be transferred to functioning organs
that make proteins important for fighting infection and inflammation (Wilson et al.,
2004). Gastrointestinal blood loss should be prevented among patients on NSAIDs or
corticosteroids. Methotrexate is not recommended for patients with hepatitis C or severe
renal impairment (Saag et al., 2008) because methotrexate can elevate liver enzymes
which can leak chemicals into the blood stream and cause toxicity to the blood (Kassas et
al., 2018). Biological agent therapies deserve negative tuberculin tests that tests for latent
tuberculosis (TB) because TNF inhibitors interfere with immune system allowing for
infections to occur, and TB is still active today. The TNF inhibitors are used for
autoimmunity, but the potency of the medication can interfere with immune responses.
However, when taken as a combination with a DMARD, the risk of infection is reduced
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because the DMARDS suppress the immune system to reduce the frequency of producing
antibodies to the biologic (Cunha, 2016). Hepatitis B reactivation is a possible occurrence
with TNF inhibitor use. Patients whose symptoms are of less than six weeks duration
might experience viral processes like parvovirus (Saag et al., 2008). Recurrent selflimited episodes of acute joint swelling predict crystal arthropathy, which means
arthrocentesis ought to be performed to assess calcium pyrophosphate dehydrate or
monosodium urate monohydrate crystals (Saag et al., 2008). To assist in conducting
diagnosis and possible choice of a given treatment strategy, patients with inflammatory
arthritis may get a prompt referral to rheumatology subspecialists to check characteristics
of given erosive changes. Hands and feet radiography should be performed to assess
patients who exhibit inflammatory back symptoms, inflammatory eye disease, or
inflammatory bowel disease that might depict spondyloarthropathy (Saag et al., 2008).
Skin findings, such as rashes that suggest systemic lupus erythematosus, systemic
sclerosis, or psoriatic arthritis, may be the cause of the rashes from an autoimmune
reaction (Wilson et al., 2004). Polymyalgia rheumatic are typically considered among
older patients incurring symptoms within their hips and shoulder; and these patients
should be asked questions based on temporal arteritis. Various myofascial trigger points
and somatic symptoms predict possible fibromyalgia that may exist alongside RA. There
may be multiple immune-mediated conditions that seem to follow the autoimmune
disease, RA (Zerbo et al., 2016).
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Efficacy-Based Treatment Guidelines for Rheumatoid Arthritis
The main treatment guidelines for RA suggest the use of DMARDs as the
mainstay therapeutic intervention for the disease. DMARDs should be administered
immediately after diagnosis to treat the condition. Early diagnosis and drug therapy using
DMARDs may help prevent structural damage, and may lead to possible remission
(Cherascu, 2011). The sooner the diagnosis, the sooner the treatments begin. Once the
treatments become active, the desirable outcome will entail reduced pain and
inflammation as well as the prevention of further destruction of the body by the disease.
Medical practitioners should begin administering the therapy to patients with RA,
who are at risk of erosive and persistent arthritis, even if they do not meet the prescribed
benchmarks for initiating the treatment. It is not absurd to start the treatment with
DMARDs before confirmation of diagnosis. Because RA takes time to diagnose, there
are outcomes of good quality randomized controlled trials (RCT) that give evidence of a
possible role of therapeutic drugs in undistinguished arthritis (Wilson et al., 2004). These
RCTs may prevent progression of radiographic damage of joint destruction and anemia
through trial and error of research (Wilson et al., 2004). The mission of the treatment is to
aim for a target. The target may be remission or low disease activity (Craven, 2017). The
disease activity may be monitored every 1-3 months (Craven, 2017). If there is not any
improvement by the 3rd month of treatment, then the physician may adjust the treatment
option (Craven, 2017). If the target trial time of the medication has been reached by the
6th month after diagnosis, the treatment options may be adjusted if there is no

29
improvement. Methotrexate is the first treatment strategy (Craven, 2017). If methotrexate
cannot be tolerated, HCQ, leflunomide or sulfasalazine are the next DMARD treatment
options of choice. ACR/ EULAR classification criteria for RA are based on the efficacy
of evidential management of RA by a large international task force (Craven, 2017). The
international task force included several departments of rheumatology all around the
world that based their decisions, principles, and recommendations on systemic literature
reviews for therapeutic strategies of RA (Smolen et al., 2017).
Monotherapy and Combination Therapy in RA
RA is an autoimmune disease that has a significant negative impact on the ability
to perform daily activities, work, and household tasks (Singh et al., 2016). The disease
symptoms need to be treated to prevent further damage to the body. Anti-RA drugs
consist of DMARDs and/or Biologics. DMARDs can slow the progression of the disease
by suppressing the body’s overactive immune and inflammatory systems (Cohen et al.,
2019). DMARDs work to decrease the pain severity, reduce the inflammation, prevent
joint damage, or reduce joint damage, and preserve the structure and function of the joints
(Cohen et al., 2019). These medications are not designed to provide immediate relief of
symptoms (Cohen et al., 2019). DMARDs are for long- term use and take weeks to
months to become active in the body. There are a variety of types of DMARDs. The
choice of which DMARD to take depends on the following: the stage and severity of the
condition, the side effects, and the patient’s personal preference which can be driven by
insurance coverage plans (Cohen et al., 2019). In combination therapy, combining
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DMARDs is frequently used as a first-line strategy that can provide a greater therapeutic
efficacy than monotherapy in some patients, but it has higher toxicity (Wilsdon & Hill,
2017). Optimal combination of a DMARD with a biologic, and the timing of the
combination therapy, has been demonstrated to have a superior outcome for some RA
patients with an inadequate response to methotrexate alone (Wilsdon & Hill, 2017).
The most used DMARD treatments are methotrexate, sulfasalazine, HCQ,
leflunomide, and azathioprine (Cohen et al., 2019). Methotrexate was originally designed
for cancer patients but was found to reduce inflammation and decrease joint damage in
RA patients (Cohen et al., 2019). It may be combined with other DMARDs or a biologic
agent if it does not adequately control the disease alone (Cohen et al., 2019). It is the
recommended first choice of treatment in the guidelines of the ACR and EULAR
(Wilsdon & Hill, 2017). Sulfasalazine (Azulfidine) is used to treat RA as well as other
rheumatic autoimmune diseases. It may be combined with other DMARDs or a biologic
agent if it does not adequately control the disease alone (Cohen et al., 2019). HCQ
(Plaquenil) was originally developed to treat malaria but was found to improve symptoms
of arthritis and lupus. It can be used in combination with other DMARDs or a biologic
(Cohen et al., 2019). Leflunomide (Arava) inhibits production of inflammatory cells to
reduce inflammation and prevent joint damage from the inflammation (Cohen et al.,
2019). It may be used in combination with DMARDs or with a biologic agent (Cohen et
al., 2019). Azathioprine (Imuran) was also developed for the treatment of cancer, RA,
lupus, and a variety of other inflammatory illnesses, and has been used in organ
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transplantation to prevent rejection of the transplanted organ (Cohen et al., 2019). This
DMARD is only taken as a combination treatment with methotrexate (Arthritis
Foundation, 2019). A systematic review using meta-analysis found that DMARDs may
reduce radiographic erosions, but their long-term use has undesirable effects on the body
(Wilsdon & Hill, 2017).
Biologic response modifiers, such as abatacept (Orencia), adalimumab (Humira),
anakinra (Kineret), baricitinib (Olumiant), certolizumab (Cimzia), etanercept (Enbrel),
golimumab (Simponi), infliximab (Remicade), rituximab (Rituxan), upadacitinib
(Rinvoq), tocilizumab (Actemra) and tofacitinib (Xeljanz) all work to target specific
pathways of the immune system that trigger inflammation (Mayo Clinic, 2019).
Etanercept, adalimumab, infliximab, certolizumab pegol, and golimumab, are all part of
the TNF inhibitor class of biologics; and abatacept, rituximab, anakinra, and tocilizumab
are part of the interleukin kinase inhibitor class of biologics (Cohen et al., 2019).
Baricitinib, tofacitinib, and upadacitinib all target the JAK pathway. Biologics target
specific cells that contribute to the manifestation of the disease (Spriggs & BoynesShuck, 2016). Monotherapy biologic medications can increase the risks of infections
because they work as blocking agents to cytokine activity (Mayo Clinic, 2019).
Cytokines are used to alert that antigens are present in the body. However, when biologic
agents are taken as a combination with a DMARD, the risk of infection is reduced,
because the DMARDS suppress the immune system to reduce the frequency of producing
antibodies to the biologic (Cunha, 2016). Before any treatment begins, the physician
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discusses benefits, risks, dosing schedule, monitoring frequency and expected results of
all considered medications for each type of therapy (Cohen et al., 2019). Ongoing
monitoring is required to identify any potential adverse effects for each patient for safety
and effectiveness of the treatment (Wilsdon & Hill, 2017). Routine assessments of
disease activity are essential for the determination of flares that occur with RA (Wilsdon
& Hill, 2017). Flares are associated with inflammation and pain. Some flares may occur
from environmental factors that cannot be controlled. Some flares may occur from certain
foods that cause an inflamed flare-up in the joints. However, constant flares may be due
to an increased activity of the disease that causes functional deterioration and
radiographic progression (Wilsdon & Hill, 2017). In this situation, medications may need
to be increased or potentially changed. To achieve the optimal goal of treatment, the best
outcomes will come from understanding the therapeutic options available, pre-treatment
evaluations, follow-up evaluations, and ongoing monitoring for any potential
complications of the disease or its treatment (Wilsdon & Hill, 2017).
The development of targeted monoclonal antibodies and small-molecule kinase
inhibitors has expanded the effective therapeutic options in RA (Wilsdon & Hill, 2017).
Each of the medications listed in the paragraph above has the ability to modify the
diseases process to varying extents depending on the individual’s immune response
(Wilsdon & Hill, 2017). Combination therapy may be used to achieve the optimal results
for RA relief in some patients, but not all. Combination therapy consists of a DMARD
and a biologic inhibitor. Conventional DMARDs combined with TNF, JAK or interleukin
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biologics can enhance treatment outcomes more than the conventional monotherapy
approach for some patients that require multiple treatment options. One of the main
transformations in the way RA is treated is the adoption of an approach whereby the
activity index of a disease is utilized as a score, a mark to aim at with the therapies.
Therefore, the approach not only focuses on the reduction score, but also remission or
low activity of the disease. Setting a treatment target, following the treatment
recommendations and principles, and applying a sequence of drug strategies, may
maximize the optimal results. Head-to-head trials comparing the efficacy and safety of
DMARDs and TNF inhibitors in patients with active RA, despite a trial and/failure of
methotrexate therapy, are inadequate due to the need for research (Smolen, et al., 2016).
An expert in RA can only prescribe therapeutic agents for RA. Therefore, it may
not seem relevant to the primary care, but the rheumatologist and primary care work
together for the better health of someone with RA. However, general practitioners ought
to understand the implication of using the drugs and their adverse effects, since they form
part of the multidisciplinary team that reviews the progress of the disease and its
treatment options. IL-23 anti-interleukin antibody treatment never reduces the activity of
the disease by a great margin among RA patients with an inadequate response to
methotrexate (ACR response 53.6% and 41.3% vs. 40.0% in placebo; Smolen et al.,
2017). The data for the compounds secukinumab and brodalumab (human anti-IL-17 RA
monoclonal antibodies) that block IL-17 and IL-23 are not effective for some patients in a
previous study (Genovese et al., 2014). Some clinical patients that had an inadequate
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response to the TNF inhibitors improved their immune response using ixekizumab (Taltz)
because it targeted the interleukin pathway (Genovese et al., 2014). Interestingly, it
remains contentious whether IL-17 and IL-23 blocking agents might be competitive
among the already approved and available compounds to treat RA (Genovese et al.,
2014).
It is important to be evaluated and treated by a rheumatologist to be placed on the
right treatment regimens. The patient may try several different types of treatment before
finding the appropriate therapy that provides relief for a better wellbeing. There are
several factors that contribute to the appropriate treatment plan. The duration and severity
of the disease, previous treatment restrictions, comorbidities, family planning,
preferences, and financial and social circumstances are some of the major issues to
consider when deciding on the appropriate treatment plan (Wilsdon & Hill, 2017). During
the pre-treatment evaluation, the patient should have baseline blood tests performed that
include a full blood examination, serum creatinine levels, liver enzyme levels, hepatitis
screening and TB screening, because abnormalities may alter the choice of therapy and
dosing (Wilsdon & Hill, 2017).
EULAR reiterates that biosimilars, which are generic drug therapies, either
approved by the U.S. Food and Drug Administration (FDA) or the European Medical
Agency (EMA), report the same safety and efficacy outcomes as the respective biological
originator, which is the brand name drug therapy (Smolen et al., 2017). Biosimilars
infliximab (Remicade), etanercept (Enbrel), and rituximab (Rituxan) are FDA approved
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biologics that were also approved by the EMA in 2017 (Generics and Biosimilars
Initiative Online, 2017). A significant series of biosimilars is still under development.
For patients who incur persistent remissions following tapered steroids, tapering
DMARDs might be a good alternative (Smolen et al., 2017). Injecting patients with 25
mg etanercept, down from 50 mg per week, or increasing the etanercept or adalimumab
injection intervals is consistent with tapering medications for the preservation of clinical
remission or low disease activity, amidst clinically relevant flare rates (Smolen et al.,
2013). Alternatively, abrupt DMARD therapy cessation results in flares among most
patients, if not all patients. However, not each of those DMARD therapies attain their
initial remission states or low disease activity. In a recent epidemiological study, 50% of
the patients involved in an ACT-Ray study stopped using tocilizumab (Actemra) a year
after sustained clinical remission (Huizinga et al., 2015). However, later in the study,
84% of the patients suffered recurrent flare-ups and were reintroduced to the tocilizumab
treatments (Huizinga et al., 2015). Within that double-blind randomized trial, the patients
under remission with certolizumab pegol (Cimzia) and a DMARD ceased getting
treatment (Huizinga et al., 2015). Three out of the seventeen patients taking certolizumab
pegol maintained remission until the 52nd week (Smolen et al., 2015). In accordance with
EULAR recommendations, when there was particularly persistent remission, tapering the
DMARDs became a good alternative. However, the recommendation is still under
investigation because most of the rheumatologists might not cease DMARDs in
remission by letting the patient go without a disease-modifying therapy (Smolen et al.,
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2017). The anti-CCP antibodies should continue being measured in patients with RA or
suspected RA while taking a combination therapeutic treatment to potentially taper
medications (Deighton et al., 2009).
Remission may be achieved through medical interventions and therapeutics
because bone erosion can be detected in 25% of RA patients within the first 3 months of
onset of symptoms (Wilsdon & Hill, 2017). In 70% of the RA patients that have not been
diagnosed with RA, bone erosion may be detected by the third year of painful symptoms
(Wilsdon & Hill, 2017). Therefore, patients whose RA is detected early and treated
immediately are less likely to have excessive bone erosion than patients that wait years
after the symptoms have begun. Delaying treatment beyond 3 months increases joint
destruction and leads to a higher chance of requiring a more persistent therapy (Wilsdon
& Hill, 2017).
RA biological drugs causing infections are on the rise. An estimated 6 out of
1,000 patients annually are being treated for infections due to biological agents, unlike
the case of DMARDs (Singh et al., 2015). Future infection prevalence depends on
glucocorticoid use, comorbidity, age, and history of severe infections as identified in the
AR-PoWER database. The rise in risks depends on the baseline risks among different
patient categories (Strangfeld et al., 2011). Therefore, public health surveillances are
deployed for daily practices to reduce the cases (Lahiri & Dixon, 2015). RCTs associated
serious inflictions among the biologic augur with the infection rates identified in antiTNF surveys among follow-up patients (Lahiri & Dixon, 2015). RA treatment guidelines
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were presented and addressed for safety concerns (Singh, Saag, & Bridges, 2016). ACR
suggests and recommends the use of DMARDs alongside TNF inhibitors, especially
among patients that have suffered severe infections in the past, despite insufficient
supporting evidence, because the DMARDs can reduce the infections of TNF biologics
by reducing the antibodies that respond to the biologic (Lahiri & Dixon, 2015).
Therefore, biologics may have less risk of infections when taken with a DMARD. RCTs
have revealed that combination therapy elicits fewer hospitalizations and less severe
infections (Schiff et al., 2008; Yun et al., 2005). The recommendations do not necessarily
apply to all patients, as some patients might not want the particular therapy. Therapy
cannot be forced on patients, but it can be recommended.
Following TNF inhibitors approval, heart failure cases have lessened when
infliximab (Remicade) is given to a patient at a dose of 10 mg/kg (Chung et al., 2003).
Infliximab is a monoclonal antibody that binds to the TNF, so the TNF cannot bind to a
receptor to trigger immune response. Similarly, the latest studies reveal that heart failure
never occurs among patients using TNF inhibitors. In fact, symptomatic congestive heart
failure risk never increases among high-risk patients that endure heart failure, while being
treated with TNF inhibitors (Emrich, 2009). In a large-scale international study, Bykerk
and associates reported that subjects using the biologic agent, tocilizumab, while
remaining on DMARD therapy demonstrated a rapid onset of effect and continued to
improve over a 6-month period (Bykerk et al., 2012).
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The risk of opportunistic infections in patients being treated with a biological
DMARD requires these patients to be tested for underlying latent TB (Salliot et al.,
2009). TB reactivation is more prevalent among patients receiving anti-TNF monoclonal
antibodies, relative to those on etanercept (Enbrel). The membrane-bound TNF plays a
crucial role in safeguarding a patient against acquiring TB. The TNF antibody neutralizes
TB, thereby reducing the infection risk (Plessner et al., 2007; Tubach et al., 2009). TNF
biologics, such as abatacept and rituximab, did not interfere with Mycobacterium
tuberculosis controls in mice studies (Bigbee et al., 2007). Minor cases of TB occur
during tofacitinib therapy, and the cases that arise are speculated as new infections the
patients acquire during clinical trials. The new TB infections manifest among some
patients because clinical trials take place in a high prevalence zone for the condition
(Winthrop et al., 2016). Tocilizumab exhibits no TB risk factors in RCTs (Singh et al.,
2016). Before enacting a treatment methodology, determining which DMARDs would be
best for results, a relevant screening methodology with a TNF inhibitor may be of better
use (Hua et al., 2004).
Methotrexate monotherapy results in vaccine impairment. Discontinuing the
methotrexate for a given period of time perfects the immunogenicity of the influenza
vaccine among patients suffering from RA (Campbell et al., 2011; Park et al., 2017).
Tofacitinib elicits little impact regarding vaccine response (Winthrop et al., 2016). TNF
inhibitors taken with tocilizumab do not lessen the vaccine response (Mori et al., 2013).
A safety issue related to tocilizumab during therapy involves large intestinal perforation
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risk. Data obtained from a European study illustrated that perforation in the large
intestine occurs in tocilizumab patients relative to those who undergo combination
treatment with DMARDs (Strangled et al., 2017). Large intestinal perforation risk does
not get resolved despite an improved concomitant glucocorticoid use within Cox
regression analysis (Strangled et al., 2017). A positive medical history regarding
diverticulitis contradicts tocilizumab use, meaning that various large intestinal perforation
issues lack diverticulitis history. Patients need to be aware of large intestinal perforation
risks and elevated inflammation markers, which may not get interpreted during the
tocilizumab therapy.
Lymphoma, non-melanoma and melanoma skin cancers, and other cancers occur
less frequently among patients using TNF inhibitors relative to patients on the standard
monotherapy DMARDs (Mercer et al., 2017). A previous study was performed to
investigate the safety of biologics and DMARDs and found that patients on TNF
compared to patients on conventional DMARDs did not have an increased risk for
malignancies in general (Ramiro et al., 2016). Rituximab (Rituxan) is more predominant
in comorbidities like lymphoproliferative disorders and concomitant multiple sclerosis
than other biological agents (Mercer et al., 2017). Between 30-40% of the patients with
RA have poor response to DMARDs (Liu et al., 2017). Therefore, a combination of
DMARDs together with various action modes of biologics is preferred by some patients.
Biologics have various roles that target specific areas of the body. TNF, JAK and
interleukins are the common targets of biologics. Interleukin-1 receptor antagonist with
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TNF inhibitors reveals the absence of additional benefits, with a minimum of two
combinations that raise the adverse events like severe infections (Weinblatt et al., 2006;
Genovese et al., 2004).
Challenges in RA Management
There are various challenges regarding the management of RA patients, coupled
with inefficient responses to the initial standard monotherapy treatment. The increasing
modes of actions and consequent DMARDs remain core issues still not addressed.
Observational data reveals advantages regarding altering the action mode within
TNF-IR inhibitors by switching to a biologic of a non-TNF. (Greenwald et al., 2011;
Emery et al., 2015). ACR suggests the application of a non-TNF biological in the event
of an inadequate response to the initial TNF inhibitor (Singh et al., 2016). In randomized
control trials and other observational studies, the non-responders to the first DMARD
therapy gave little clinical response following the conversion to a second trial using a
TNF inhibitor in co-therapy (Bombardieri et al., 2004; Remy et al., 2011; Schiff et al.,
2014). Cytokines, other than TNFs, might perform disease mediation among primary
non-responders; and then the patients might experience additional benefits based on
compounded use of various action modes instead of just TNF blocking (Bombardieri et
al., 2004; Remy et al., 2011; Schiff et al., 2014). A previous study recommended a
second TNF inhibitor, or the deployment of agents with different action modes that have
no hierarchical ranks, was recommended in a case if a TNF inhibitor fails (Rubbert-Roth
& Finckh, 2009). Combination therapy is recommended for therapy non-responders.
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Nearly 60% of patients that switch to a second TNF inhibitor following primary
failure of the first TNF inhibitor attain a reduction in their disease activity score (DAS)28 by a minimum of 1.2 points (Mease et al., 2010). DAS-28 is the 28th version that
measures disease activity in the 28 joints being examined (NRAS, 2019). The
examination includes swelling, pain, tenderness, RA specific inflammation markers, xrays, and questionnaires (NRAS, 2019). The DAS-28 score is calculated using a unique
formula. The scores > 5.1 is high disease activity, < 5.1 is moderate disease activity, <
3.2 is low disease activity, and < 2.6 is remission (NRAS, 2019).
Patients who do not respond to TNF inhibitors may require secondary treatment
measures. Arguably, the medications might have lost response from developing anti-drug
antibodies, which makes the patient exhibit a clinical non-response to a given anti-genetic
form of treatment. Data obtained from various randomized controlled placebo trials
demonstrate safety and efficacy when it comes to TNF alpha inhibitors, such as
certolizumab (Cimzia), among RA patients under secondary response inadequacy due to
adverse effects of the first TNF or TNF inhibitor intolerance (Jani et al., 2014). The TNF
alpha inhibitors block the activity of TNF alpha markers in the body and reduce the TNF
alpha levels to help decrease the RA symptoms (Ellis & Hein, 2016). Patients who
develop antibodies during their initial use of a TNF inhibitor are more at risk of
developing further antibodies upon TNF inhibitors. TNF inhibitors are anti-TNF and can
cause a rise in antibodies when taken as monotherapy because the immune system is
responding to block inflammation. This side effect is good reason to take them with a
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DMARD that lowers the antibody response. Immunogenicity might be the primary cause
of lower clinical efficacy of a second TNF inhibitor as seen in the case of TNF-IR. In this
scenario, altering the treatment option among patients who exhibit failure on TNF
inhibitors might be a worthy alternative. For instance, the biologic agents golimumab,
abatacept, rituximab, tocilizumab, and tofacitinib have been shown to elicit high levels of
clinical positive response especially among patients that inadequately responded to a
minimum of one TNF inhibitor (Genovese et al., 2016).
Direct evaluations of compounds from different action modes in TNF-IR do not
exist. In addition, there are minimal data available on the safety and efficacy of TNF
inhibitors following non-TNF-inhibiting DMARDs failure, and a second failure of IL-6
receptor inhibitor after tocilizumab had failed (Emery et al., 2008). Basically, the choice
of following a DMARD from TNF-IR is not yet settled upon, apart from EULAR and
ACR that recommend alternating to non-TNF biologicals in the case where a second TNF
inhibitor failed (Virkki et al., 2011).
Apart from the observational data and making indirect comparisons, combination
therapy comparisons to monotherapy all point to a reduced risk of infections (Rein &
Mueller, 2017). No consensus has been reached regarding CD20 monoclonal antibody
applications in patients undergoing rituximab (Rituxan) therapy (Cohen et al., 2006).
Rituximab is a monoclonal antibody that targets the CD20 b-cells. B-cells play a major
role in RA because the cytokines are released from the b-cells in response to the
observance of a foreign antigen. However, in autoimmune diseases, the healthy cells in
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the body become the foreign antigens. Therefore, an overproduction of inflammation
occurs that leads to structural damage. The efficacy of b-cell depletion therapy using antiCD20 rituximab is a major advance in RA therapy because of the role of b-cells in RA
pathogenesis (Chen & Cohen, 2012). A collection of safety data has established a well
safety profile for TNF inhibitors in RA treatments (Rubbert-Roth & Finckh, 2009).
Abatacept (Orencia) exhibits a relatively accepted safety profile (Schiff et al., 2008). In
contrast, a meta-analysis indicates an increase in adverse events risk with certolizumab
pegol (Cimzia) use in the first treatment month (Smolen et al., 2009). RCTs for TNF
inhibitors seek washout phase of 4 weeks minimum of no treatment after a trial following
the previous injection or TNF inhibitor infusion (Smolen et al., 2009). ARRIVE, ACTSURE, and EXXELARATE are clinical trials that refute the need for the washout phase
(Smolen et al., 2009).
Rheumatologists have alternative treatment options to choose from other than
TNF inhibitors, as well as different action modes and administrative routes. Tocilizumab,
rituximab and abatacept are generally approved for intravenous access or subcutaneous
use. Studies which compare the subcutaneous and intravenous administrative routes of
these treatment agents reveal no major difference in clinical safety and efficacy apart
from reactions that result at the subcutaneous injection site (Gabay et al., 2013;
Burmester et al., 2016). Abatacept and rituximab reveals that alternating from a weekly
subcutaneous TNF injection to intravenous treatments is safe and effective; and might fill
a 4-week gap of treatments within one infusion (Mueller et al., 2016). In addition, 50% of
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the patients receiving subcutaneous injections in real life did not feel comfortable
injecting themselves and preferred intravenous infusions (Mueller et al., 2016).
Measures Outcome in Rheumatoid Arthritis Therapy
Within the evaluation of the disease, multiple variables can be dependent or
independent, whose interpretation often depends on clinical judgment. In a 1994 study,
with 9 years of follow-up research, the researchers found that reduced educational levels
correlated with decreased function and increased mortality of RA (Pincus et al., 1994).
Patients underwent psychological tests and measurements of disability. An attempt was
made to correlate their psychological state with the disease activity for the patients that
did not have improving results during the three-year follow-up period (Pincus et al.,
1994). Therefore, RA can affect brain activity. Another study carried out on 122 women
patients with RA using logistic regression showed that the ability to control work hours
and family support were variables that contributed to improving the patient’s ability to
work.
Another study was conducted with a 2-year follow-up in patients with potential
predictors of sustained remission for 2 years that observed the DAS-28 and CRP in
patients using a multivariate analysis (Lee et al., 2017). Age, pain, disease aggression,
functional disability index obtained from the Health Assessment Questionnaire Disability
Index, and depression evaluated by the Arthritis Impact Measurement Scales were all
factors with a prediction of remission of RA symptoms (Lee et al., 2017). The study
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indicated that Health Assessment Questionnaire (HAQ) scores are useful when stratifying
RA patients in accordance with their risk for flare-ups (Lee et al., 2017).
In 2003, a study was done to determine the prognostic factors of disability in early
RA, as well as the effects on a radiographic scale and the functional course of the disease
in patients with RA of less than a year who were followed-up for 5 years (Berner et al.,
2018). The study resulted in a high HAQ score correlated with pain, elevated DAS-28,
higher painful joint counts, and the presence of erosions by the last follow-up (Berner et
al., 2018). Gender, age, RF scores, IgM or IgA antibodies, and class II genes did not
contribute significantly to predicting a five-year disability (Pincus et al., 2016). Authors
suggest that RF may act as an enhancer of bone loss (Van Steenbergen et al., 2015). The
following year, a systematic review concluded that part of the functional outcome at work
depends on a biopsychosocial mismatch between the capacity of the individual and the
demands of work (Pincus et al., 2016). Rheumatologists often use a Multidimensional
Health Assessment Questionnaire (MDHAQ) and/or a Routine Assessment of Patient
Index Data to measure the patient’s disease activity and performances on their treatments
(Chua et al., 2017). Quantitative data from these MDHAQs have provided much valuable
information for research studies using secondary data (Chua et al., 2017). A benefit of
using quantitative methodology is to facilitate access to evidence-based secondary data
rather than primary data (Gopalakrishnan & Ganeshkumar, 2013). According to the ACR
rates, 20% or greater reported patient improvement in functional disability as reflected by
the assessment scores for HAQ disability index (Genovese et al., 2005).
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Summarization of Therapy
It should be considered that RA is a potentially catastrophic disease that requires
energetic management once the diagnosis of the disease has been established. The
ultimate goal of such treatment is to try to achieve a remission of the disease by putting
into play the best available therapeutic resources. A particularly important premise for the
treatment of RA is to start treating the disease as early and as aggressively as possible.
Several studies have shown that combination therapy using two DMARDs has better
results than monotherapy DMARDs; and even the combination of three DMARDs may
be better than two DMARDs (Nocturne et al., 2016). Although treatments using
DMARDs without a biologic, including combination DMARDS, can be therapeutic for
the signs and symptoms of the disease, the control is not enough to inhibit the structural
joint damage for some patients. In those cases, it may be important to consider the use of
biological agents that have been patient effective, not only for the control of signs and
symptoms, but also to decrease and inhibit articular damage (Cutolo & Sulli, 2018).
Over the last 50 years, the treatment strategy of RA was designed on the
erroneous premise that the prognosis of the disease, in general, was favorable. It is
currently known that the majority of patients with active RA are clinically disabled
within the first 20 years of the disease, and that more than 90% of patients with synovitis
have radiological evidence of erosions in the first 2 years after diagnosis despite
conventional treatment with Functional Antibiotic Resistance Metagenomic Element
(Nocturne et al., 2016).
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Although a cure is not a viable goal, remission may be. A proposal for the
treatment of RA was presented a few years ago in which monotherapy DMARD to be
used less and less based on growing evidence that biologic agents may be more efficient
(Cutolo & Sulli, 2018). However, that is not the standard treatment being utilized by
rheumatologists. Therefore, more research needs to be performed for accuracy. RA
centers are still overwhelmed with patients performing trial and error on medications.
This study looked at a comparison of monotherapy and combination treatments using
biologics at population levels to determine whether there is a difference between
treatments for Caucasian women between the ages of 30 and 60 years.
The effectiveness of newly developed biological response modifiers has been
demonstrated (Olson et al., 2016). The biologic modifiers, TNF, JAK and interleukins,
target specific cytokines that have an important role in perpetuating the inflammation of
RA through specific pathways (Ajeganova et al., 2017; Olson et al., 2016).
Recent information shows that early administration of DMARDs leads to clinical
improvement and delays in the radiological progression of the disease as it has been
found to occur with the use of methotrexate, leflunomide, sulfasalazine, HCQ,
cyclosporine, minocycline, azathioprine, D-penicillamine and intramuscular gold (Tan &
Smolen, 2016). All share some characteristics, such as the slow start of the action and a
mechanism of action that is not well elucidated. In a meta-analysis of blinded and
controlled studies, it was found that the relative potency of the majority of DMARDs
were similar, but the HCQ and intramuscular gold were less potent (Tan, & Smolen,
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2016). Compared with methotrexate, leflunomide has similar efficacy for control of
clinical variables of disease activity and radiological progression (Arntz et al., 2018).
The literature on combination therapy with DMARDs refers to methotrexate as
the cornerstone of therapeutic schemes. The first clinical study of combination therapy
with methotrexate was made in 1995 in patients with partial response to methotrexate at
the maximum tolerated doses by adding cyclosporin (2.5 to 5 mg/kg) or placebo (Sterne
et al., 2016). Patients who received both DMARDs had a 25% improvement in both the
painful joint count compared to the placebo group (p = 0.02); and 25% improvement in
the count of swollen joints (p = 0.005) compared to the group that received only
methotrexate (Goodman, 2015). The main toxicity was the increase in serum creatinine
(Goodman, 2015).
In another study, 155 adult patients with RA of less than 2 years duration were
randomized to either combined treatment of prednisolone (60 mg/day), oral methotrexate
(7.5 mg/semester) and sulfasalazine (2 g/day); or sulfasalazine (2 g/day) as the only
DMARD (Ter Wee et al., 2017). At week 40, the treatment was similar to week 28. In the
combination therapy group, the prednisolone had been reduced until it was suspended at
week 28, and the methotrexate was suspended until week 40 (Ter Wee et al., 2017). The
researcher wanted to see a change in the RA symptoms by suspending medications. Until
28 weeks, the sulfasalazine was taken alone, and then after 28 weeks, it was taken in
combination with the Prednisolone, and then a third DMARD was added at week 40,
which was methotrexate. At week 28, the combined therapy group improved significantly
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more than the sulfasalazine group alone (Ter Wee et al., 2017). Although the clinical
improvement was similar after week 28, the radiological benefit (delay of bone damage)
persisted after five years. The results of this study suggest the concept that using
glucocorticoids or other medications as induction therapy yields long-term benefits.
Although glucocorticoids are not included as DMARDs, recent studies have
demonstrated their ability to slow bone damage in early RA, although the side effects
limit their use for prolonged periods as monotherapy for the control of RA (Goodman,
2015). Glucocorticoids in equivalent doses of 10 mg or less of prednisone per day are
used to treat 30 to 60% of patients with RA (Goodman, 2015). The use of combination
therapy of DMARDs until less than a decade ago was not so common, but now more than
30% of RA patients are treated with combination DMARD therapy. This increase has
been due to the results of studies that demonstrated the additional benefit of adding
another DMARD to patients on methotrexate with active disease (Cutolo & Sulli, 2018).
With methotrexate as the only DMARD, one-third of patients improved 50% after 2-4
years; and the addition of oral folic acid prevented liver toxicity (elevation of
transaminases) without reducing the efficacy of methotrexate (Cutolo & Sulli, 2018).
Oral and parenteral therapy of methotrexate has fallen into disuse due to its prolonged
initiation of intolerable side effects (Taylor et al., 2019). Subcutaneous is the preferred
method of administration (Taylor et al., 2019).
There is no cure for RA (Wilson et al., 2004). The present treatments focus on
slowing disease progression and providing symptomatic relief (Wilson et al., 2004).
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DMARDs are the main choice of treatment for RA (Rubbert-Roth & Finckh, 2009).
Methotrexate was the initial commonly used treatment, and it was effective on standard
clinical measures of DAS and was cost-effective (Rubbert-Roth & Finckh, 2009). It was
not well tolerated, however. Biologic agents were a major advance in the treatment of RA
(Rubbert-Roth & Finckh, 2009). The biologic agents target immune effector cells (T
lymphocytes, B lymphocytes and macrophages), which are responsible for inflammation
and structural damage in affected joints, bone, organs and the signaling molecules
involved in their activation (Rubbert-Roth & Finckh, 2009). TNF inhibitors were the first
approved biologic agents for the treatment of RA (Rubbert-Roth & Finckh, 2009). TNF
inhibitors are effective at improving RA symptoms and slowing or preventing structural
damage (Rubbert-Roth & Finckh, 2009). Biologics are intended to inhibit inappropriate
cytokine activity and have been used with substantial efficacy to alter the progression of
RA by targeting cells and molecules that are thought to be functionally important to the
biologic pathway (Wilson et al., 2004). DMARDs target the entire immune system, and
biologics target specific areas of the inflammatory process. When taken as a combination,
DMARDS suppress the immune system to reduce the frequency of the infectious
antibodies being produced in response to the biologic. In combination, the DMARDs
lower the antibodies being produced and the biologic targets the specific inflammatory
sites by working as an inflammatory blocking agent.
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Chapter 3: Research Method
Research and Rationale
This study compared the therapeutic efficacy of DMARD treatments with a
biologic to DMARDs without a biologic at population levels for Caucasian Alabamian
women aged 30 to 60 years that have been diagnosed with RA. The study focused on the
effectiveness of the two groups, monotherapy DMARD treatments and combination
treatments with a biologic, for the target population using the following additional
covariates: age of patient, anti-rheumatic action of treatment, and DAS. Data required for
answering the stated research question were obtained from the AR-PoWER database
which was a research network of patients with RA that provides data from patientcentered research associated with PCORnet (Fleurence et al., 2014). By and large, the
study was quantitatively built on the tenets of a cross-sectional study in which secondary
data were used to test the stated hypothesis.
Methodology
The study was quantitative. It focused on a cross-sectional study design that was
used to analyze the association between variables using statistical analyses (Grand
Canyon University, Center for Innovation in Research and Teaching [CIRT], 2019). The
methods style was observational and used a predicted hypothesis. Quantitative research
requires that the statistical data be reliable and measured accurately (CIRT, 2019). This
methodology used a nominal and ordinal scale of measurement to distinguish between the
groups (CIRT, 2019). Therefore, the object measured was placed into categories (CIRT,
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2019). Logistic regression was the statistical method used for this study to analyze the
relationship between an outcome (dependent variable) and two or more predictors
(independent variables). Logistic regression is useful in research to explain the
relationship between the independent variables and the outcome. The model does not
assume a sequence of random variables, statistical normality, or linearity (Starkweather
& Moske, 2011). In this study, the three independent variables (predictor variables) were
the anti-rheumatic actions of treatment (DMARDs with a biologic and DMARDs without
a biologic), DAS, and age. The dependent variable, which was dichotomous, was the
therapeutic effectiveness of RA treatments. The control variables were gender, ethnicity,
and diagnoses.
Population
The population was based on location, gender, age, and ethnicity. The population
data were derived from the AR-PoWER national database that focuses on patients that
reside in the United States for the purposes of data collection and analysis at population
levels. Since RA is 2-3 times more common in women than men, the study population
was composed of women with RA. The age range for this population was 30 to 60 years.
Although RA can affect all ethnicities, this research was limited to Caucasians. The
therapeutic efficacy of combining DMARDs and biologics has never been
comprehensively studied at these population data levels. The rheumatology clinics stay
full of patients and may take up to a year for initial evaluation. For example, the
rheumatology clinic at the University of Alabama (UAB) handles more than 20,000
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patient visits annually, which is about 80 patients a day, and the majority of the patients
are women (UAB, 2020).
Sample Size Estimation
The statistical software used for the sample size determination was the g*power
3.1.9.4 version, as indicated below:
z tests - Logistic regression
Options: Large sample
Analysis: A priori: Compute required sample size
Input:
Tail(s)
= One
Pr(Y=1|X=1) H1
= 0.1
Pr(Y=1|X=1) H0
= 0.2
α err prob
= 0.05
Power (1-β err prob)
= 0.95
R² other X
= 0
X distribution
= Normal
X parm μ
= 0
X parm σ
= 1
Output: Critical z
= -1.6448536
Total sample size
= 103
Actual power
= 0.9502378
The scores of the variables were calculated through a nominal scoring. G*Power
is a statistical software that was used to calculate effective sample size according to the
statistical testing that was used. The appropriate testing was contingent on the hypothesis.
According to the G*Power analysis, this study needed to have 103 total participants to
have an appropriate sample size with a probability value of 0.05. The probability value
determines the statistical significance of the output for each participant data being tested.
This study included 100 cases, which consisted of two independent study groups.
Group 1 included 51 cases using DMARD treatments without a biologic (monotherapy
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DMARD group). Group 2 included 49 cases using DMARD treatments with a biologic
(combination DMARD & biologic group).
Sampling
The sampled data collection was of the target population. The database, ARPoWER, consisted of secondary data that were randomly selected. The selection was
performed by stratified random sampling. The data were separated from the bulk
population into exclusive sub-population sets, such as gender, age, and ethnicity. Once
the exclusive sub-population parameters were set, the simple random data sampling
began by obtaining 100 random samples from the stratified random selection of data to
structure a test group. Stratified random sampling ensures that the subgroups within the
population provide better coverage of the population because there is more control over
the subgroups to ensure that all groups are represented in the sampling (Murphy, 2019).
Stratified random sampling reflects the population being studied more accurately than
simple random sampling because it divides the population into subgroups, rather than
merely choosing subjects from an entire population (Murphy, 2019). Choosing from an
entire population group without parameters can cause potential confounding in the study.
Data Collection
Data were collected through the AR-PoWER national database. The patients had
already signed consent forms that their results may be used for research, but their
personal information would not be released. The data used were categorical data that
indicated how each patient rated her medication according to the patient’s success or
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improvement while on the medication. The data were specific to the population
requirements for the study. Therefore, parameters were set for the data according to
Caucasian women aged 30 to 60. Once the parameters were indicated, the data chosen for
the study were presented at random according to their treatment plan. There were 50
cases collected for the monotherapy DMARD group and 50 cases for the combination
biologic group to perform chi-square statistical testing and logistic regression.
Operationalization of Constructs
This research was quantitative in nature. The quantitative statistical analysis
involved a small data collection from the data presented to AR-PoWER database from
actual RA results that were submitted from actual patients. The data used secondary data
for the purpose of integrating valid and reliable findings in this research (Gopalakrishnan
& Ganeshkumar, 2013). The statistical test performed for this research was logistic
regression that models a binary outcome of three independent variable groups in the same
population: the anti-rheumatic action of treatment (DMARDs with a biologic and
DMARDs without a biologic), DAS, and age. The actual data for the study were
secondary data from the national database AR-PoWER, which includes data obtained
from the UAB Hospital of Rheumatology. The random cases were assigned to the
conditions based on the above criteria of the baseline characteristics. The data were
randomly assigned through the national database. A contingency table was formed to
enter the categories of the independent variables to be analyzed with the dependent
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variable. Each column represented an observational subject with the nominal categorical
variables. Each row was represented by the individual sample numbered 1-100.
Statistical Data Analysis
Logistic regression was used to predict a nominal dependent variable with
nominal categorical independent variables (Laerd Statistics, 2018) and any covariates that
consisted of continuous and nominal variables that related to the dependent variable. The
dependent variable for this study was the therapeutic effectiveness of RA treatments. The
dependent variable contained binary nominal categories (No = 0, Yes = 1). The
covariates for this study were: age of patient, anti-rheumatic action of treatment, and
DAS. The covariates are the independent variables in a logistic regression model. Each of
the three independent variables being analyzed were all categorical. All the independent
variables were entered into the dialog box for covariates because in the Statistical
Package for the Social Sciences (SPSS) software for logistic regression models, if the
independent variables relate to the dependent variable, then all will be tested as
covariates. The values were entered into SPSS for analyzing the dataset to determine an
outcome (Laerd Statistics, 2018). SPSS was used to compute the data and provide a
logistic distribution based on the relationship between the independent and dependent
variables. This statistical model produced parameter estimates that analyze how much
each predictor variable contributes to the likelihood of the outcome. If the p-value is less
than or equal to significance level (alpha-α) of 0.05, then the null hypothesis can be
rejected which means there was a difference in the therapeutic efficacy between
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combination therapy and monotherapy in treating RA patients, and the alternate
hypothesis is supported (Bruin, 2006). The variables and cases were first entered into a
crosstab contingency table for the logistic regression model. The 100 test cases were
entered in rows. The test variables were entered in the columns. A statistical output was
generated. The regression test provided a predictor model of percentages for the
DMARDs with and without a biologic that are therapeutically effective. The logistic
regression provided a classification table that explained how good the model was at
predicting the outcome. In this study, it represented the percentage of how good the
model predicated the therapeutic efficacy of the DMARDs with and without a biologic. A
logistic regression can provide an odds ratio (OR) table that provides the odds of the
therapeutic effectiveness of DMARDs with a biologic and without a biologic. The higher
the ratio, the better the odds are for therapeutic efficacy. A model summary was provided
that detailed the “R squared” percentage that explained how much of the outcome
(therapeutic effectiveness) was explained by the predictor variables (DMARDs with and
without a biologic).
Potential Confounders
Potential confounders can cause bias in the data by increasing the variance of the
dependent variable. Confounders act as additional independent variables that are not
included in the study. Potential confounders for this study consisted of the year that the
medication was started, the year the medication was ended, the year that the patient
entered into the AR-PoWER database and the name of the medications. This study was
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performed on women only. Gender was a restricted variable and was not a confounder.
Whether the patient had insurance and/or a comorbidity may affect the data and be
permitted as a potential confounder as well.
Threats to Validity
The lack of multiple experimentation may be a threat to the validity of the
research. Multiple experiments were needed for replication and cross-validation before
the results can be theoretically interpreted with confidence (Ohlund & Yu, n.d.).
Therefore, the choice of testing was a factor for internal validity. A potential factor for
external validity was multiple treatment interference. Patients with RA tried several
different medications prescribed by the physician for a yearning of pain relief. Therefore,
the multiple changes in treatment options could have interfered with the effects of the
current treatment (Ohlund & Yu, n.d.).
Methods Summary
Is there a difference in the therapeutic efficacy of combination DMARD
treatments with a biologic, compared to monotherapy DMARDs without a biologic, in
U.S. Caucasian women between the ages of 30 and 60 that have been diagnosed with
RA? This research may be used for future comparisons with other research at population
levels to compare differences among populations. The data were collected through the
AR-PoWER National database for an estimated fifty samples for each treatment group
(Group 1: Monotherapy and Group 2: Combination Therapy). The data were sampled
using stratified random sampling. The research was quantitative in nature. The statistical
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test performed was logistic regression that compared the relationship of the two
independent predictors in the same population to the dependent outcome. There was a
contingency table to enter the categories for the variables to be analyzed in SPSS. The
logistic regression generated a comparative analysis among the predictor variables to the
outcome. Logistic regression and chi-square testing were performed to reduce any
potential threats to validity through statistical analysis. The comparative analysis using
logistic regression and chi-square testing were both used for a two-way association
between the monotherapy treatments and the combination treatments for women patients
with RA. The logistic regression adjusted for age.
Hypothesis
Is there a difference in the therapeutic efficacy of combination DMARD treatments with
a biologic, compared to monotherapy DMARDs without a biologic, in U.S. Caucasian
women between the ages of 30 and 60 that have been diagnosed with RA?
Null Hypothesis: There is no difference in the therapeutic efficacy between
combination therapy and monotherapy in treating U.S. Caucasian women between the
ages of 30 and 60 that have been diagnosed with RA.
Alternative Hypothesis: There is a difference in the therapeutic efficacy between
combination therapy and monotherapy in treating U.S. Caucasian women between the
ages of 30 and 60 that have been diagnosed with RA.
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Chapter 4: Results
Introduction
The purpose of this study was to compare the therapeutic efficacy of RA
treatments between monotherapy DMARD drug treatments and combination therapy
drug treatments in women aged 30 to 60 years. A quantitative methodology was used to
compare monotherapy treatments to combination therapy treatments using secondary data
from the AR-PoWER database. The goal was to reveal a variation of differences in the
forms of treatments (DMARD with a biologic and DMARD without a biologic) as the
basic formation of statistical analysis. Logistic regression was performed, and it
presented no association between the effectiveness of the treatments to the anti-rheumatic
action, such as a monotherapy DMARD or a combination DMARD with a biologic.
Research Question Analysis
Is there a difference in the therapeutic efficacy of combination DMARD
treatments with a biologic, compared to monotherapy DMARDs without a biologic, in
U.S. Caucasian women between the ages of 30 and 60 that have been diagnosed with
RA?
The dependent variable (i.e., the therapeutic effectiveness of RA treatments) and
the association of the independent variables (i.e., the antirheumatic action of treatment:
monotherapy DMARD treatments and combination DMARD with biologic treatments,
DAS, and age) were examined using the following hypothesis:
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Null Hypothesis: There is no difference in the therapeutic efficacy between
combination therapy and monotherapy in treating U.S. Caucasian women between the
ages of 30 and 60 that have been diagnosed with RA.
Alternative Hypothesis: There is a difference in the therapeutic efficacy between
combination therapy and monotherapy in treating U.S. Caucasian women between the
ages of 30 and 60 that have been diagnosed with RA.
The following data sections (data collections, results, and summary) will detail
the data process further and produce an interpretation of the results.
Data Collection
The data collection began the day after Christmas 2020, 3 days after the IRB data
approval of the research agreement with Global Healthy Living Foundation (GHLF) for
the use of their database AR-PoWER. The data obtained from the database were
consistent with the variables described in Chapter 3. The selection of the data was
performed by stratified random sampling of 100 cases that were Caucasian women aged
30 to 60 years. The participants were assigned to the database according to their baseline
conditions which were women patients diagnosed with RA. The data collection
originated from the actual RA results submitted from actual patients to the AR-PoWER
database through the GHLF. The descriptive statistics were calculated using SPSS. A chisquare test provided an unadjusted two-way association to test the hypothesis. A logistic
regression was performed as well, which allowed the data to be adjusted for age.
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The categorical dependent variable indicated whether the medication was
effective as indicated by the patient’s improvement while on the medication. The
independent variables were categorized by the two groups: monotherapy treatments and
the combination treatments. The independent variables consisted of the following: three
different age groups of patients: 30-39, 40-49, and 50-60; the DAS; and the antirheumatic action of treatment (which was the monotherapy and combination therapy drug
treatments).
Results of Descriptive Statistics
The data consisted of a small sample of 100 cases. There were no missing cases.
A frequency distribution was analyzed to summarize the measurements of the categorical
independent variables. There were 100 total cases observed for age of patient (Table 1).
Out of the 100 cases, 17% were aged 30-39 years, 37% were aged 40-49 years, and 46%
were aged 50-60 years.
Table 1
The Proportion of Research Participants by Age Group
Age groups

Frequency

Percent
17

Valid
percent
17

Cumulative
percent
17

30-39

17

40-49

37

37

37

54

50-60

46

46

46

100

Total

100

100

100
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Regarding the type of treatment, as seen in Table 2, 51% of the patients used a
DMARD monotherapy regimen, and 49% of the patients used a biologic regimen with a
DMARD concurrently.
Table 2
The Proportion of Research Participants by the Anti-Rheumatic Action of Treatment
Anti-rheumatic action
of treatment

Frequency

Percent

Valid
percent

Cumulative
percent

DMARD monotherapy

51

51

51

51

Biologic combination

49

49

49

100

Total

100

100

100

The frequency distribution of the DAS can be seen in Table 3. Out of the 100
cases, 2% scored in remission range with their regimen; 4% scored low disease activity
with their regimen; 37% scored moderate disease activity with their regimen; and 57%
scored high disease activity with their regimen. Thus, only 6% of the patients succeeded
with their regimen to receive the goal of remission to low disease activity. A
crosstabulation was performed to observe how the DAS was affected by the monotherapy
DMARD treatments and the combination treatments with a biologic and a DMARD
(Table 4). Out of the 2% of the patients that scored in the remission range, all were
treated with a monotherapy DMARD. Out of the 4% of the patients that scored in the low
disease activity range, only one patient received combination therapy, while the other
three patients were treated with a monotherapy DMARD. Out of the 37% that scored in
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the moderate range, there were 28 patients on combination therapy and 29 patients on
monotherapy.
Table 3
The Proportion of Research Participants by the Disease Activity Score
Frequency

Percent
2.0

Valid
percent
2.0

Cumulative
percent
2.0

< 2.6: Disease
remission

2

2.6 – 3.2: Low
disease activity

4

4.0

4.0

6.0

3.2 – 5.1:
Moderate
disease activity

37

37.0

37.0

43.0

>5.1: High
disease activity

57

57.0

57.0

100.0

Total

100

100

100
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Table 4
The Cross-Tabulation of the Anti-Rheumatic Action of Treatment & Disease Activity
Score
< 2.6:
Disease
remission
score

2.6 – 3.1:
Low
disease
activity
score

3.2 – 5.1:
Moderate
disease
activity score

>5.1: High
disease
activity
score

Total
cases

Monotherapy
DMARD

2

3

17

29

51

Combination
biologic &
DMARD

0

1

20

28

49

Total
frequency

2

4

37

57

100

Antirheumatic
action of
treatment

Results of Chi-Square Tests
A chi-square analysis provided a two-way association between the independent
variables and the dependent variable. The cross tabulation provided a verification that the
test itself was consistent with the data. A table was developed (Table 5) that presented a
relationship between the dependent variable (Effectiveness of Treatment) and the
independent variable (Age of Patient). Fourteen patients from age group 30-39 stated the
medications were effective, and three patients stated that the medications were not
effective. Thirty patients from age group 40-49 stated that the medications were effective,
and seven patients stated that the medications were not effective. Thirty-nine patients
from age group 50-60 stated that the medications were effective, and seven patients stated
that the medications were not effective. Table 6 provided the chi-square analysis. The
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Pearson value of 0.205 indicated that there was not much association. The p-value was
0.902 which was above the alpha level of 0.05. I failed to reject the null hypothesis that
there is no difference between the combination therapy and monotherapy in treating RA
patients based on the lack of association of the effectiveness of treatments and the ages of
the patients.
Table 5
The Cross-Tabulation of the Effectiveness of Treatment & Age of Patient

Effectiveness
of
treatment
Effectiveness
of
treatment

Age group:
30 - 39

Age group:
40 - 49

Age group:
50 - 60

Total

Yes

14

30

39

83

No

3

7

7

17

17

37

46

100

Total

Table 6
The Chi-Square Test: Effectiveness of Treatment & Age of Patient
Value

DF

P-Value

Pearson chi-square

.205

2

.902

Likelihood ratio

.205

2

.902

N of valid cases
100
* 1 cell (16.7%) have expected count less than 5. The minimum expected count was 2.89.
(This is still below the 20%, so the assumption has not been violated).
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A cross-tabulation was developed (Table 7) that presented a relationship between
the dependent variable (Effectiveness of Treatment) and the independent variable (AntiRheumatic Action of Treatment). Forty-four patients stated the DMARD monotherapy
treatments were effective, and seven patients stated that the DMARD monotherapy
treatments were not effective. Thirty-nine patients stated the biologic combination
treatments were effective, and 10 patients stated that the biologic combination treatments
were not effective. Thus, 83% of the patients stated that their regimen was effective,
whether it be monotherapy DMARD treatments or biologic combination treatments.
Table 8 provides the chi-square analysis. The Pearson value, which was 0.791, indicated
there was some variation and slight association. However, the p-value was 0.374 which
was above the alpha level of 0.05. Therefore, I failed to reject the null hypothesis for the
association of the effectiveness of treatments and the anti-rheumatic action of treatment.
Table 7
The Cross-Tabulation of the Effectiveness of Treatment & Anti-Rheumatic Action of
Treatment
Monotherapy Combination
DMARD
biologic &
DMARD
Effectiveness
of
treatment
Effectiveness
of
treatment
Total

Total

Yes

44

39

83

No

7

10

17

51

49

100
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Table 8
The Chi-Square Test: Effectiveness of Treatment & Anti-Rheumatic Action of Treatment
Value

Df

Pearson chi-square

.791

1

.374

Likelihood ratio

.794

1

.373

Continuity
correction

.388

1

.533

Fisher’s exact test

P-Value

Exact
sig. (2sided)

Exact
sig. (1sided)

.432

.267

N of valid cases
100
* 0 cells (0.0%) have expected count less than 5. The minimum expected count was 8.33.
Results of Logistic Regression Model
A logistic regression was performed to determine whether there was an
association between the type of RA drug treatment and its effectiveness. The dependent
variable was the outcome, the effectiveness of the treatments. The dependent variable
was coded categorically according to the effectiveness: 0 = no, 1 = yes. The independent
variables were indicated as covariates in SPSS. There were three independent variables.
The first independent variable was categorized according to the anti-rheumatic action of
the drug treatment: the DMARD monotherapy drug treatments and the combination
biological drug treatment with a DMARD. Another independent variable was age of the
individuals set in three age groups: 30-39 (n=17), 40-49 (n=37), and 50-60 (n=46). The
last independent variable was the DAS which was measured by the swelling and achiness
of the joints: 0 = score < 2.6 (patient in disease remission), 1 = score 2.6 – 3.1 (patient
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with low disease activity), 2 = score 3.2 – 5.1 (patient with moderate disease activity),
and 3 = score >5.1 (patient with high disease activity).
The log likelihood summary contains the R² statistic which provides
representation that the model is a good fit for the data. The “Cox and Snell R Square”
calculated the variation among the independent variables in association with the
dependent variables. The “Nagelkerke R Square” measures the same and is typically
between 0 and 1. The Cox and Snell are usually more conservative with the calculation.
According to the model summary, there was a 4 – 6.8% variation that explained the
therapeutic efficacy of RA treatments among the three independent variables. Therefore,
the model built for this study did fit the data. However, the stronger the model, the higher
the R² statistic. An algorithm was computed for the likelihood ratio (LR) = 87.050.
Therefore, the model did hold true to provide an estimation of “good enough” fit for the
data.
The Hosmer and Lemeshow Test is a goodness-of-fit statistical test. This test
works well for variables with a binary response. As in this study, there was a binary
response of “yes” the treatment was effective or “no” the treatment was not effective.
Hosmer and Lemeshow tests are used in logistic regression to measure whether a model
is satisfactory for the study. The significant value determines if the model is a poor fit if,
p < 0.050. The significant value for this study was > 5%; p < 0.585. Therefore, this
model was an adequate fit for the data.
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The logistic regression model provided details as to whether or not the model had
a significant association between the effectiveness of the treatments and the predictor
independent variables. The coefficients of the model were labeled “B”. A positive
coefficient with a p ≤ 0.050 would indicate a positive association between the variables.
The data in Table 9 did not support a significant association between the predictor
variables and the outcome variable. In standard regression coefficients (B), the null
hypothesis must have a value ≤ 0 in a population; and the alternative hypothesis would
have a value > 0. The coefficients for the logistic regression in this study were < 0 and
supported the null hypothesis. In addition, the coefficients were also the log odds that
relate to the linearity of the independent variables (Table 9).
The OR of the model was labeled “Exp. B”. In a standard regression, if OR = 1,
then there is no relationship between the independent and dependent variables. If the odds
ratio is > or < 1, then there could be a potential relationship between the variables. The
age of the patient OR = 1.150, which could have a potential relationship with the
dependent variable. The action of treatment OR = 0.638, and the DAS OR = 0.480, which
are both < 1, which could mean that there was a potential relationship between the
independent variables and the dependent variable. However, the significant value of the
variables was > 0.050 which indicated there was no association.
The 95% confidence interval (C.I.) is useful for hypothesis testing. In a standard
regression, if the upper and lower bounds go through 1 then the model supports the null
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hypothesis. As in this study, the 95% C.I. for each of the predictor variables supported
the null hypothesis.
Logistic regression requires no multicollinearity (strong correlation) among
independent variables. This can be measured is SPSS by observing the collinearity
diagnostics of the independent variables. The collinearity of two or more scale
independent variables must be tested and tested again in reverse order to measure for any
strong correlation. The threshold for the variance inflation factor (VIF) is 3. Therefore,
any VIF greater than 3 may potentially have multicollinearity issues. The VIF for this
study was 1.000 for each of the two variables tested. Also, there were not many
independent variables for this study, thus decreasing the probability of multicollinearity.
Table 9
The Logistic Regression Model – Variables in the Equation
B

S.E.

Wald

Df

Sig.

Exp. B

95%
C.I.
Upper
.567

95%
C.I.
Lower
2.333

Age of
Patient

.140

.361

.151

1

.698

1.150

Action of
Treatmen
t
Disease
Activity
Score

-.449

.546

.676

1

.411

.638

.219

1.862

-.735

.519

2.004

1

.157

.480

.173

1.327

Constant

3.550

1.513

5.505

1

.019

34.798
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Summary
The purpose of this study was to compare the effects of the DMARD
monotherapy drug treatments and the biologic combination drug treatments with a
DMARD. The Cox and Snell R², Nagelkerke R², and Hosmer and Lemeshow Tests are
all in agreement that the model fits the data. However, according to the data in relation to
the statistical associations of variables, there was no significant evidence that supported
the alternative hypothesis. The logistic regression coefficients in the model were < 0. The
null hypothesis had been failed to be rejected. The 95% C.I. was in the appropriate range
for null hypotheses. The chi-square models also supported the null; there was no
association between the variables. The null hypothesis was not rejected in any of the
tests. In lieu of all the evidence, there was no significant difference in the therapeutic
efficacy of RA treatments. The monotherapy drug treatments were no more or less
effective than the combination therapy drug treatments, according to the logistic
regression model. The logistic regression model met all requirements for the analysis to
test the hypothesis. The research question, “Is there a difference in the therapeutic
efficacy of combination DMARD treatments with a biologic, compared to monotherapy
DMARDs without a biologic, in U.S. Caucasian women between the ages of 30 and 60
that have been diagnosed with RA?”, was answered by there was no significant
difference in the drug treatments for RA. RA is an autoimmune disease that will affect
each individual differently. The medications that are prescribed will respond to each
individual’s cellular structure differently.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The purpose of this study was to compare the therapeutic efficacy of RA
treatments between monotherapy DMARD and combination therapy of DMARD plus
biologic using quantitative statistical analysis. The goal was to reveal a variation of
differences in the forms of treatments as the basic formation of statistical analysis. The
chi-square tests and the logistic regression generated a comparative analysis among the
predictor variables to the outcome variable. The chi-square test results were important for
testing the hypothesis in addition to the logistic regression model. While the chi-square
tests provided an unadjusted two-way association, the logistic regression model observed
the same association, but adjusted for age. The p-value for the chi-square tests did not
significantly indicate an association, and I therefore did not reject the null hypothesis.
The logistic regression model also reported a low statistical power in failing to reject the
null hypothesis.
Previous research investigated the safety of biologics and DMARDs and observed
the clinical patient responses to the medications individually. Previous studies identified
prognostic factors of RA and calculated their disease activity. I conducted a quantitative
correlational design to analyze the association between predictor variables and the
outcome variable using statistical analyses of secondary data. Correlation designs are an
observation of data collection and not for cause and effect (CIRT, 2019). This methods
style was observational and uses a predicted hypothesis. The chi-square tests are
specifically tested for correlation. The logistic regression is a predictive analysis that
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explains the relationship between the variables. In this study, the three independent
variables (predictor variables) were the anti-rheumatic actions of treatment (DMARDs
with a biologic and DMARDs without a biologic), DAS, and age. The dependent variable
was indicated as the therapeutic effectiveness of RA treatments. There was no statistical
association between these variables in this study.
Interpretation of the Findings
This study was conducted on 100 RA data cases. There were two sub-groups that
were used as predictor variables. The monotherapy DMARD sub-group contained 51
cases, and the combination biologic and DMARD sub-group contained 49 cases. A
sample size estimation was performed prior to the analysis using the G*power statistical
software 3.1.9.4 version. The analytical software indicated an estimation of 103 data
cases was needed for the study. Therefore, the total number of cases was slightly under
the estimated recommendation by three cases.
A chi-square test was performed to evaluate a possible association between the
effectiveness of the treatment (dependent variable) and the age of the patient
(independent variable). The test was not statistically significant with p = 0.902. I failed to
reject the null hypothesis. A chi-square test was performed to evaluate a possible
association between the effectiveness of the treatment (dependent variable) and the antirheumatic action of treatment (independent variable). The test was not statistically
significant with p = 0.374. I failed to reject the null hypothesis. The chi-square test was
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not able to be performed on DAS (independent variable) because it was continuous data;
it contained interval data that was measured according to a scale.
The statistical analysis for this study found no association between the dependent
variable and the independent variables. Therefore, there was no significant difference
between the monotherapy treatments and combination treatments for the therapeutic
effectiveness for RA. The results of this study were not consistent with the research
findings of other researchers, such as Cutolo and Sulli (2018), who were observing
osteoclastic functioning of RA patients using biologic DMARD therapy. However, the
results of this study were consistent with the research findings of Parida et al. (2015) who
were comparing the efficacy and infectious side effects of non-biologics versus biologics.
Those researchers found that monotherapy, combination therapy, and triple therapy of
non-biologics (DMARDs) were similar to the efficacy of combination anti-TNF biologic
agents with methotrexate, and this was observed across various populations (Parida et al.,
2015).
This research did not support the idea that combination drug treatments using a
DMARD, and a biologic agent are more effective than monotherapy DMARD treatments
for the population studied. In fact, the results of the logistic regression and chi-square
testing of this study provided evidential support that there is no difference in the
treatments for the specific population of Caucasian women aged 30 to 60 years. The pvalues for these tests were not significant and therefore indicated no association between
the effectiveness of the treatments and the predictor independent variables. The
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coefficients for the logistic regression in this study were < 0 and supported the null
hypothesis.
Limitations of the Study
Limitations are characteristic constraints that result in unanticipated challenges
within the study. There were several limitations to this study that needed to be addressed.
One limitation was that this study was conducted using secondary data. The data were
patient reported to the GHLF and incorporated into the AR-PoWER Database. Most of
the data were obtained from a large source, the UAB Rheumatology Hospital in
Birmingham, Alabama. However, the database is a national database, and I was not able
to determine that all the data came from UAB as opposed to from another rheumatology
clinic. A second limitation is that the data observed Caucasian women only and was not
compared to other ethnicities or gender. A third limitation was the sample size. The
sample size of 100 cases was slightly smaller than recommended. A larger sample size
could potentially provide more precision. A fourth limitation was in the methodology.
More independent variables could have possibly yielded different results. However, there
was limited access to the specifics of the secondary data, such as the time the medications
were tried and stopped, as well as the location of the patient, which resulted in
unavailability of further data. The only data that was available was the gender, race,
disease activity score, medication taken, and if it was stopped or continued. A fifth
limitation is that the participants had comorbidities that altered their DAS. However, this
information was unavailable from the database.
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Recommendations for Further Study
The findings of this study may help enhance the knowledge on how to
appropriately use DMARD and biologic treatments to control the inflammatory response
to prevent severe bone erosion and joint deformity. The literature may provide
knowledge on potential comorbidities that follow the autoimmune disease, such as
cardiovascular and pulmonary diseases. The statistical analysis may close the gap in
literature for Caucasian women ages 30 to 60 years on the therapeutic efficacy of
DMARD treatments that stop the inflammatory cells from being produced and the
biologic treatments that stop the immune system from being overactive. Although
combination biologic DMARD therapy may work well together for some RA patients, it
is not a standard treatment for all patients. According to the results of this study, there
was no difference in the therapeutic efficacy between combination therapy and
monotherapy in treating U.S. Caucasian women between the ages of 30 and 60 years that
have been diagnosed with RA. Public health, insurance providers and physicians are the
ones that design the policies of standard regimen for diseases. This research can possibly
make an impact on their policies of treatments for patients being diagnosed with RA. The
findings of this study may help bring social change by providing evidence as related to
the efficacy of combination therapy for RA, compared to the standard monotherapy
treatment, which would be valuable in developing more effective clinical and/or public
health practices for healthcare policy regulations to ensure regulatory standards are being
met. With all potential benefits being stated, I would recommend that future studies
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broaden the research by comparing data from other ethnicities and gender. I would also
recommend incorporating comorbidities to see if it would influence the findings of the
study. A retrospective cohort study would be recommended to incorporate time analysis
as well as comparative analysis.
Implications for Positive Social Change
The purpose of this study was to compare the therapeutic efficacy of RA
treatments. A positive social change implication of this study’s findings is that the
assessment of the efficacy of DMARDs with a biologic agent and DMARDs without a
biologic agent may warrant further investigation in which studies with large sample sizes
that include various populations are used. In this study, there was no difference between
the monotherapy and combination therapy treatments for Caucasian women aged 30 to 60
years. The findings of this study did not influence medical policies for public health
issues on the effectiveness of combination therapeutics as the potential RA standard
regimen.
It is apparent that the prescribed treatments for the autoimmune disease will
respond to each individual’s cellular structure differently. Biological agents are made in a
laboratory from living organisms. These agents target specific cellular pathways in the
body. Each RA patient will have inflammatory responses due to various reasons whether
it be environmental, infectious, genetic, or hormonal. There is not a specific RA test that
determines which type of biologic is needed, so it is trial and error. For example,
biologics that target interleukins will use a recombinant monoclonal anti-interleukin
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receptor to interrupt the pathway. However, if the patient’s RA is not flaring from
inflammation in the interleukin pathway, that biologic will not work. Then, the patient
must wait for the medications half-life or until the medication has exited from the
bloodstream. Conventional DMARDs are immunosuppressive agents. These drugs are
initial treatments because they have less severe side effects on the body. DMARDs are
good for long-term use, but do not activate as quickly as a biologic. The disease activity
and severity, comorbidities, allergies, and even patient preference (including cost, oral
administration versus injection administration, and frequency of monitoring) all play a
pivotal role in the determination of DMARD therapy (Benjamin, Bansal, Goyal &Lappin,
2020). However, all DMARDs work the same by suppressing inflammatory responses no
matter the pathway.
Conclusion
RA is an autoimmune disease that can attack the entire body through
inflammation. DMARD treatments target the entire immune system, whilst biologics
target specific areas of the inflammatory process. When taken as a combination, the
DMARD can suppress the immune system to reduce the frequency of the infectious
antibodies being produced in response to the biological agent. This occurrence is relevant
for combination treatments because the DMARDs lower the antibodies being produced
while biologic agents target specific inflammatory sites, such as TNF or interleukins, by
working a blocking agent. However, the results for this study did not find a significant
association between the effectiveness of the drug treatments with the anti-rheumatic
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monotherapy treatments or the combination action of treatment. Having adjusted for age,
logistic regression was used to examine the association between the therapeutic
effectiveness and the treatment modality (DMARDs without a biological agent and
DMARDs with a biologic agent) with an OR > 1 for age; OR < 1 for DAS and action of
treatment; all of which had a potential relationship with the dependent variable.
Therefore, the action of treatment, DMARD with a biologic and DMARD without a
biologic, had < 1% effectiveness on a therapeutic outcome. However, the significant
value result indicated that there was no significant association between treatment
effectiveness and treatment modality. Therefore, according to the statistical findings of
this study, the combination drug treatments were no more or less effective than the
monotherapy therapy drug treatments. The effectiveness of the treatment depends on the
cellular structure of the individual.
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